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ABSTRACT 
 
Obesity and type 2 diabetes are the most prevalent metabolic diseases affecting over 50% of 
people in the western world.  Although the pathogenesis of type 2 diabetes is not fully 
understood, growing evidence links this disease to a state of chronic inflammation, which 
occurs in metabolically active tissue such as the liver, adipose tissue and skeletal muscle and 
results in the secretion of inflammatory cytokines, of which interleukin-6 (IL-6) is one.  It is 
generally accepted that elevations in the plasma and/or tissue of this family of cytokines have 
a negative effect on whole body glucose homeostasis.  While there is compelling evidence for 
the negative effects of resistin and TNF-α on insulin sensitivity, the role of IL-6 in the 
etiology of insulin resistance is not fully understood.  The notion of negative effects of IL-6 in 
metabolic processes is further confounded by the marked elevations of IL-6 which occur in 
conjunction with the beneficial activity of exercise.  We firstly sought to examine the effect of 
the lipolytic hormone adrenaline on IL-6 expression and release in order to establish whether 
IL-6 acts independently of adrenaline in the regulation of fat metabolism.  Reporting the 
absence of an effect of adrenaline on IL-6, we then investigated the role of IL-6 on metabolic 
processes in humans at rest and during exercise in circumstances where lipolysis was 
inhibited.  Marked increases in IL-6 circulating protein and tissue gene expression were 
observed with exercise and further so with fatty acid suppression.  In a mouse model of IL-6 
depletion marked insulin sensitivity was observed, which was reversed with IL-6 treatment.  
In a mouse model with normal endogenous IL-6 levels IL-6 treatment also impaired glucose 
tolerance.  Contrastingly, in a rat model both chronic and acute IL-6 treatment improved 
glucose tolerance  
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In summary, studies from this thesis suggest that, rather than being causally related to insulin 
resistance, the cytokine IL-6 increases lipolysis, fat oxidation, and glucose metabolism in 
insulin sensitive tissues in humans.  This does not appear to be the case in the mouse, where 
contrasting actions are observed, perhaps due to differences in the reliance of various 
parameters for metabolic processes between the species. 
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CHAPTER ONE   
 
 
INTRODUCTION AND LITERATURE REVIEW 
 4
 
1.1 General introduction 
 
Interleukin-6 (IL-6) was originally identified and reported by several groups, thus receiving a 
variety of different identifying names reflecting its multifunctional characteristics (Kamimura 
et al., 2003).  The protein was originally sequenced 25 years ago (Weissenbach et al., 1980), 
and it was cloned and structurally characterized almost 20 years ago by Hirano (Hirano et al., 
1986), and Yasukawa and colleagues (Yasukawa et al., 1987).  The diverse repertoire of IL-6 
expression includes T and B cells, carcinoma cells, endothelial cells, macrophages, mast cells, 
dendritic cells, islet β cells, and more recently has been found to be expressed in and released 
from adipose tissue (Mohamed-Ali et al., 1997; Fasshauer et al., 2004), skeletal (Chan et al., 
2004a)  and smooth  (Zampetaki et al., 2005) muscle cells (Chan et al., 2004a; Zampetaki et 
al., 2005).  Many immunomodulatory functions have been ascribed to IL-6, as reviewed by 
Hirano and colleagues (Hirano et al., 1990).  However, more recently IL-6 has been shown to 
act on a number of tissues, whose principal roles are not of an inflammatory nature (Febbraio 
& Pedersen, 2002).  The recent findings that IL-6 is both a prominent “adipokine” (Lazar, 
2005) and “myokine” (Febbraio & Pedersen, 2005) has lead to much interest in the role of 
this cytokine on metabolic processes during health and disease. 
 
1.2 Induction of interleukin-6 and subsequent signal transduction 
 
IL-6 production is stimulated in response to a variety of stimuli.  The signalling events 
leading to IL-6 production due to pathological stressors such as reactive oxygen species (Frost 
et al., 2003) and the inflammatory cytokines IL-1 and TNFα have been well established 
(Akira et al., 1993).  Pathogens such as lipopolysaccharide also potently induce IL-6 
production by mounting an innate immune response through toll-like receptors in skeletal 
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muscle and immune cells (Frost et al., 2005).  Additionally, it has been known for some time 
know that IL-6 is produced from contracting skeletal muscle in the absence of inflammation 
(Febbraio & Pedersen, 2005).  The differential factors regulating contraction-induced versus 
inflammation-induced IL-6 production have not been fully described.  Factors increasing 
concomitantly with exercise have been implicated in IL-6 production independently of 
exercise.   
 
The calcium ionophore, ionomycin, potently increases IL-6 transcription in muscle cell 
culture (Keller et al., 2002. J Phys 539:31 abstract).  Under mechanical load, cytosolic Ca2+ 
levels increase dramatically and could thus stimulate contraction-induced IL-6 production. 
Prolonged contractile activity is characterised by low-amplitude and sustained elevations in 
intracellular Ca2+, leading to increased activity of calcineurin, a ubiquitous Ca2+–calmodulin-
dependent protein phosphatase known to be a key mediator of Ca2+ signalling in muscle cells, 
and contraction-induced IL-6 transcription has recently been associated with enhanced 
calcineurin activity (Banzet et al., 2005).  Free fatty acids also induce IL-6 production in 
adipose and muscle cell culture (Weigert et al., 2004; Ajuwon & Spurlock, 2005; Jove et al., 
2005).  The greater free fatty acid levels in exercise make a likely candidate for contraction-
induced IL-6 production.  Furthermore, there is evidence to suggest that adrenergic regulation 
may be important in regulating IL-6 as administration of adrenaline increases plasma IL-6 in 
both rats (DeRijk et al., 1994) and humans (Sondergaard et al., 2000).  During exercise the 
increase in plasma adrenaline is marked and correlates with increases in IL-6 (Papanicolaou et 
al., 1996) leading to the hypothesis that the increase in circulating adrenaline could mediate 
IL-6 production (Nehlsen-Cannarella et al., 1997; Nieman et al., 1998; Nieman et al., 2003).  
Mitogen-activated protein kinases (MAPK) (Luo et al., 2003) and more specifically the 
nuclear phosphorylation of p38 MAPK (Chan et al., 2004b) also appears to regulate IL-6 gene 
transcription in exercising (Chan et al., 2004b) and non-exercising states (Luo et al., 2003; 
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Chan et al., 2004b).  The complexity of the interaction of these and likely many more factors 
signalling IL-6 production remain to be revealed. 
 
In a target cell, IL-6 can simultaneously elicit signals through its receptor complex, IL-6Rα 
and gp130, which can be functionally distinct or sometimes contradictory.  To explain how 
IL-6 is capable of generating pro-inflammatory or anti-inflammatory effects contingent on the 
in vivo environmental circumstance Hirano and colleagues (Hirano et al., 1997; Hirano, 1999) 
eloquently applied the concept of the ‘signal orchestration model’ whereby the ‘final 
physiological output can be thought of as a consequence of the orchestration of the diverse 
signalling pathways generated by a given ligand’.  IL-6 signal transduction occurs when IL-6 
binds with either its membrane bound receptor α subunit (IL-6Rα) (Taga et al., 1989) or a 
cleaved soluble version of the membrane-bound receptor (sIL-6Rα) (Mullberg et al., 1993; 
Mullberg et al., 1994).  Although IL-6 can bind to IL-6Rα, gp130 is required for formation of 
the high-affinity receptor and generation of signal transduction (Yamasaki et al., 1988; Taga 
et al., 1989; Hibi et al., 1990).  IL-6 is able to function in a wide variety of systems (eg 
immune system, acute-phase reaction, nervous and endocrine systems, cancer, bone 
metabolism, hematopoiesis) and many human diseases in the body due to the widespread 
distribution of gp130 and shedding of the soluble form of the IL-6Rα (Kamimura et al., 
2003).  For example, cells that have either no or very low expression of IL-6Rα, but express 
gp130, such as skeletal muscle (Helgren et al., 1994; Kami et al., 2000; Zhang et al., 2000) 
are potentially responsive to cytokine stimulation as facilitated by the presence of sIL-6Rα 
(Ishihara & Hirano, 2002; Jones & Rose-John, 2002; Ernst & Jenkins, 2004).  Regulation of 
gp130 signalling is considerably complex since the pleiotropic family of IL-6-related 
cytokines (IL-11, LIF, OsM, CT-1, CNTF, CLC) share the use of gp130 as a common 
receptor subunit and thus, gp130 signalling regulates a multitude of aspects involved in 
cellular and tissue homeostasis.  IL-6 and IL-11 bind specific α-receptors and induce gp130 
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homodimerisation, LIF and OsM directly induce gp130/LIF heterodimerisation, whereas 
CNTF binds to an α-receptor inducing heterodimerisation of the gp130 and LIF receptors, 
which trigger intracellular signalling cascades.  Formation of receptor complexes and 
signalling are not specifically limited to the interaction between a cytokine and its α-receptor 
alone as a large variety of receptor complexes are possible.  To highlight this, the IL-6R can 
serve as a substitute α-receptor for CNTF, enabling functional assembly of the receptor 
complex (Schuster et al., 2003).  Ultimately, the IL-6 family of cytokines activate a limited 
number of intracellular signalling cascades such as JAK/STAT and Ras/MAPK.  Tissue-
specific responsiveness is limited at the extracellular surface by restricted expression profiles 
of α-receptors and regulated local and rapid cytokine production.   
 
Following IL-6/IL-6Rα or IL-11/IL-11Rα binding, gp130 homodimerizes (Murakami et al., 
1993) and a hexameric signalling-competent complex with a stoichiometry of 2:2:2 (Ward et 
al., 1994) is formed (picture).  Binding of all other cytokines of the IL-6-related family 
induces heterodimerization of gp130 with a structurally and functionally similar β subunit, 
LIFRβ or OsMRβ.  Membrane association of α subunits is not required for signal initiation.  
Therefore, soluble α subunits can be synthesised locally and bind to ligands, which facilitate β 
subunit dimerization and generate cellular responses.   Where this occurs in the absence of 
membrane-associated α subunits it is referred to as receptor conversion or trans-signalling 
(Ernst & Jenkins, 2004).  The manner in which these interactions and signals ultimately elicit 
specificity in their response is complex and is reviewed in detail by Ernst & Jenkins (Ernst & 
Jenkins, 2004).   
 
Specific regions of the IL-6 protein have been revealed as important sites for receptor binding 
and signal transduction (Kamimura et al., 2003), and cellular effects are induced through 
signalling via the JAK/STAT pathway.  In particular, activation involves members of the 
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Janus-activated protein kinases (JAK), JAK1, JAK2 and TYK2, which then phosphorylate 
and activate the signal transducer and activator of transcription (STAT)-1 and -3 (Heinrich et 
al., 1998).  Cytokines, which signal through STAT induce transcription of a family of proteins 
known as the suppressors of cytokine signalling (SOCS) (Starr et al., 1997).  Several 
STAT1/3 consensus binding sites are located on the distal portion of all β subunits.  Ligand-
induced β subunit homo- or heterodimerization and tyrosine phosphorylation by constitutively 
associated JAK family kinases is essential for subsequent activation of STAT1/3 and 
SHP2/ERK mitogen-activate protein kinases (MAPK) intracellular signalling cascades.  JAKs 
tyrosine phosphorylate receptor-bound SHP2 causing Ras/ERK and Akt pathway activation.  
JAKs also phosphorylate receptor-bound STAT1/3, which form homo or heterodimers then 
translocate to the nucleus to activate target genes.  Negative regulation of gp130 complex 
signalling may involve proteosomal degradation of ligand-bound receptor complex 
components due to STAT3-mediated induction of SOCS1/3 or attenuation of signalling by 
tyrosine phosphorylated SHP2 via inactivation of JAKs.  Additionally, nuclear translocation 
and target gene activation can be inhibited by protein inhibitors of activated STAT proteins, 
which sequester STAT and thus prevent dimerization.  More detailed regulation of these 
pathways are reviewed by Ernst & Jenkins (Ernst & Jenkins, 2004).  The IL-6 family of 
cytokines are thought to elicit their divergent cellular responses by way of different thresholds 
of activation of STAT1/3 and SHP2.  Such mechanisms utilise multi-site phosphorylation 
(initiating signal diversity and altering strength and duration of signalling) and multi-faceted 
negative regulatory processes (restricting target gene activation) (Ernst & Jenkins, 2004), the 
details of which are beyond the scope of this literature review. 
 
Downstream signalling pathways generated by IL-6/IL-6R/gp130 and other gp130-associated 
complexes are diverse and elicit respective biological effects by activating different sets of 
genes.  Many immunological roles for downstream targets of cytokine receptors have been 
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well described.  However, other functions are beginning to emerge, whereby roles in the 
control of metabolism are becoming evident.  Primary downstream effectors of IL-6 
signalling such as MAPKs (p38, p42/44, c-jun N-terminal kinase, JNK), inhibitor of kappa B 
kinase (IκK) (Marette, 2002) and AMP-activated protein kinase (AMPK) (Carey et al in 
review after revision; Kelly et al., 2004) are known to activate processes associated with 
glucose uptake and fat oxidation 
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Figure 1.1  Schematic representation of the association of IL-6 in the formation  of active 
receptor complexes and known downstream targets of gp130-dependent signalling cascades. 
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1.3 Interleukin-6 in states of health  
 
IL-6 is produced by a large and diverse population of cells, thus, it is difficult to elucidate the 
relative contribution of each cell type to the relatively low circulating levels (< 4 pg.ml-1) 
observed in the basal state of healthy individuals (Kado et al., 1999; Bastard et al., 2000; 
Pickup et al., 2000b; Starkie et al., 2001b; Vozarova et al., 2001).  The rapid clearance rate of 
circulating IL-6 levels, whether induced endogenously (Steensberg et al., 2001a) or 
exogenously through infusion of high physiological doses (Steensberg et al., 2003b; van Hall 
et al., 2003), makes it difficult to isolate the in vivo cellular/tissue sources.  It has been 
demonstrated that in healthy humans at rest the brain releases detectable amounts of IL-6 
(Nybo et al., 2002), while the hepatosplanchnic viscera has a small uptake of IL-6 (Febbraio 
et al., 2003a).  Human subcutaneous adipose tissue both expresses and releases IL-6 in vivo 
under non-inflammatory healthy resting conditions.  This release has been estimated to 
contribute ~30% of the circulating IL-6 levels at rest (Mohamed-Ali et al., 1997; Lyngso et 
al., 2002a) and is exacerbated after exercise (Lyngso et al., 2002a; Keller et al., 2003a).   
Skeletal muscle cells express IL-6 mRNA and protein in the basal state (Hiscock et al., 2004), 
however, their contribution to circulating levels at rest appears to be negligible (Febbraio et 
al., 2003c).  Of note, IL-6 has also been shown to stimulate its own expression in skeletal 
muscle (Keller et al., 2003b) and adipocytes (Fasshauer et al., 2004). 
 
The detection of increased systemic levels of IL-6 after physical exercise is a remarkably 
consistent finding.  It has been repeatedly demonstrated that during muscular exercise the 
plasma concentration of IL-6 increases (Drenth et al., 1995; Papanicolaou et al., 1996; 
Ostrowski et al., 2000; Starkie et al., 2000; Steensberg et al., 2000; Keller et al., 2001; 
Mazzeo et al., 2001; Starkie et al., 2001a; Steensberg et al., 2001b; Langberg et al., 2002; 
Lyngso et al., 2002a; Steensberg et al., 2002; Suzuki et al., 2002; Febbraio et al., 2003a; 
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Febbraio et al., 2003b; Febbraio et al., 2003c; Helge et al., 2003; Hiscock et al., 2003; Keller 
et al., 2003a; MacDonald et al., 2003; Nieman et al., 2003; Lundby & Steensberg, 2004) in 
some circumstances more than 100 fold (Starkie et al., 2000; Suzuki et al., 2002).  IL-6 is 
produced in and released from contracting skeletal muscle during exercise over and above 
basal levels (Febbraio & Pedersen, 2002) and is hence referred to as a “myokine” (Febbraio & 
Pedersen, 2005).  Numerous studies have shown increases in skeletal muscle IL-6 mRNA in 
both humans (Steensberg et al., 2000; Keller et al., 2001; Starkie et al., 2001a; Steensberg et 
al., 2001a; Steensberg et al., 2002; Febbraio et al., 2003b; Keller et al., 2003b; Lancaster et 
al., 2003; Nieman et al., 2003; Chan et al., 2004a; Fischer et al., 2004) and rodents (Jonsdottir 
et al., 2000), as well as net release of IL-6 from the contracting limb (Steensberg et al., 2000; 
Steensberg et al., 2001a; Steensberg et al., 2002; Febbraio et al., 2003c; Helge et al., 2003) 
following exercise, which accounts for the majority of the marked systemic elevation of IL-6 
observed during exercise (Steensberg et al., 2000).  Adipose tissue (Lyngso et al., 2002a), 
brain (Nybo et al., 2002), and peri-tendon (Langberg et al., 2002) have also been identified as 
tissues, which increase gene transcription and or protein release of IL-6 following exercise, 
thus contributing to elevated circulating levels.  
 
The appearance of IL-6 into the circulation after exercise is subject to exercise intensity 
(Ostrowski et al., 2000; Lundby & Steensberg, 2004), duration (Nybo et al., 2002) and mode 
(Nielsen et al., 1996; Nieman et al., 1998; Starkie et al., 2001a).  Additionally, the energy 
status of, or supply to, the working muscle is another factor.  Carbohydrate feeding during 
exercise consistently attenuates the increases in plasma IL-6 (Nehlsen-Cannarella et al., 1997; 
Starkie et al., 2001a; Febbraio et al., 2003b; Keller et al., 2003a; Nieman et al., 2003).  
Consistent with the effect of different modes of exercise, IL-6 gene expression in the 
contracting skeletal muscle has been shown to be attenuated (Nieman et al., 2003) or 
unaffected (Starkie et al., 2001a) by carbohydrate ingestion.  Moreover, this release is 
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potentiated by low-intramuscular glycogen stores (Keller et al., 2001; Steensberg et al., 
2001a; Helge et al., 2003; MacDonald et al., 2003; Chan et al., 2004a).  The effects of 
exercise on IL-6 levels have been associated with concomitant increases in glucose uptake 
(Febbraio et al., 2003c; Helge et al., 2003).  High and low doses of IL-6 infused into healthy 
humans (Steensberg et al., 2003c) and rats (Rotter Sopasakis et al., 2004) under resting 
conditions have been shown to have no effect on whole-body glucose disposal (Steensberg et 
al., 2003c; Rotter Sopasakis et al., 2004), endogenous glucose production, or leg-glucose 
uptake (Steensberg et al., 2003c).  When a low-intensity exercise bout was supplemented with 
IL-6 administration, to achieve circulating levels observed in a high-intensity exercise bout, 
the rate of glucose appearance and the rate of whole body glucose disposal, and thus the 
metabolic clearance rate of glucose, were increased above levels achieved with exercise alone 
(Febbraio et al., 2004).  Stouthard and colleagues (Stouthard et al., 1995) infused human 
subjects with a high dose of recombinant human IL-6 (rhIL-6) and reported that it increased 
whole body glucose disposal and subsequent oxidation.  However, administration of 
physiological doses of IL-6, corresponding to plasma concentrations obtained during 
prolonged exercise, did not affect glucose metabolism (Steensberg et al., 2003c).  Thus, it is 
likely that IL-6 is linked to regulation of glucose homeostasis during exercise and or that it 
acts as a carbohydrate sensor, while in the absence of contraction-induced stimuli, 
physiological doses of IL-6 alone are not sufficient to induce hepatic glucose out-put or 
increase glucose disposal. 
 
Petersen and colleagues, and van Hall and colleagues demonstrated that IL-6 infusion into 
healthy (van Hall et al., 2003) and type 2 diabetic (Petersen et al., 2005a) patients elevated 
circulating fatty acid (FA) levels and increased FA turnover, without reducing glucose 
turnover, causing adverse side effects, or causing hypertriacylglyceridemia, and that these 
effects of IL-6 were acting independently to changes in circulating hormones.  In vitro 
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investigations show that IL-6 increases lipolysis in adipocytes originating from human breast 
(Path et al., 2001), subcutaneous (Petersen et al., 2005a) and omental (Trujillo et al., 2004) 
depots, without the presence of hormones (Trujillo et al., 2004) and without altering basal or 
insulin-stimulated glucose transport (Path et al., 2001).  Pulse-chase studies on excised rats 
muscles incubated in the presence of IL-6 display increased exogenous and endogenous FA 
oxidation without effect on FA uptake or incorporation of FA into endogenous lipid pools.  
Furthermore, IL-6 attenuated insulin's suppressive effect on FA oxidation, increasing 
exogenous FA oxidation (Bruce & Dyck, 2004).  It is also reported that AMPK activity is 
elevated skeletal muscle and adipocytes when incubated in the presence of IL-6 (Kelly et al., 
2004).  Consistent with this, FA and triacylglycerol concentrations increased in a dose-
dependent manner when rats were infused with IL-6 (Nonogaki et al., 1995).  The temporal 
profile of post-exercise IL-6 output from abdominal subcutaneous adipose tissue of healthy 
subjects closely resembles that of glycerol and FFA (Lyngso et al., 2002b).  Of note, 
however, the IL-6 release begins approximately 30 min before glycerol and fatty acid outputs 
begin to increase, suggesting that this IL-6 production post-exercise may influence lipolysis 
and fatty acid mobilisation rate from this lipid depot (Lyngso et al., 2002a).  When 
contracting skeletal muscle is confronted with increasing concentrations of fatty acids 
originating from other tissues, energy utilization should be favored in the muscle, while other 
organs act as energy suppliers.  Thus, IL-6 released from the contracting muscle and adipose 
tissue may trigger energy supply through paracrine and autocrine lipolytic actions on adipose 
tissue.  In general, the weight of evidence suggests that IL-6 may be a contributing factor to 
the health benefits associated with exercise; improved fatty acid metabolism, glucose 
tolerance, and insulin sensitivity.  Despite recent literature indicating such beneficial effects, 
IL-6 is commonly attributed a causative role in metabolic disease, largely because small 
elevations in circulating IL-6 are often seen in obese and insulin resistant patient populations. 
 15
1.4 Interleukin-6 in states of metabolic disease 
 
Circulating IL-6 is strongly associated with obesity and is often used as a predictor of the 
development of type 2 diabetes  (Kern et al., 2001).  Substantial evidence also indicates that 
obesity is accompanied by a low-level inflammatory state.  The release of cytokines by 
adipose tissue (“adipokines”) contributes to the inflammatory state observed in obesity.  
Monocytes infiltrate adipose tissue in proportion to adiposity and can be a source of adipose 
tissue-derived inflammatory cytokines (Weisberg et al., 2003).  Supporting the connection 
between obesity, inflammation, and insulin resistance, IL-6 and TNFα directly cause insulin 
resistance in model systems (Hotamisligil et al., 1994; Emanuelli et al., 2001; Senn et al., 
2002; Rotter et al., 2003; Senn et al., 2003).  A range of investigators conclude that IL-6 
decreases (Bastard et al., 2002; Senn et al., 2002; Klover et al., 2003; Lagathu et al., 2003; 
Rotter et al., 2003), increases (Stouthard et al., 1995; Stouthard et al., 1996; Wallenius et al., 
2002b; Carey et al. in review after revision), or has no effect (Steensberg et al., 2003c; 
Petersen et al., 2005a) on insulin sensitivity.  In addition,  the measurement of IL-6 levels and 
gene polymorphisms in relation to insulin sensitivity is equivocal (Makino et al., 1998; 
Bastard et al., 2002).   Thus, the cause or effect relationship between IL-6 and insulin 
resistance and the development of type 2 diabetes has not been completely resolved.   
 
While IL-6 leads to insulin resistance in rodent liver tissue, its role in skeletal muscle and 
adipose tissue is unclear.  Liver cells treated with IL-6 demonstrate reduced insulin-stimulated 
glycogen synthase activity, blunted glycogen phosphorylase, decreased glycogen synthesis, 
and increased glycogen breakdown (Kanemaki et al., 1998).  Insulin receptor signalling is 
also impaired in IL-6 treated liver through inhibition of receptor autophosphorylation, 
tyrosine phosphorylation of IRS-1 and subsequent activation of PI3-K and Akt through 
stimulation of the insulin receptor inhibitor, SOCS3 (Senn et al., 2002; Klover et al., 2003).  
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Muscle tissue insulin action is inhibited in vivo by IL-6 (Kim et al., 2004a).  When mice (Kim 
et al., 2004b) and differentiated myotubes (Rieusset et al., 2004) were acutely treated with IL-
6 before or during insulin stimulation, glucose disposal and skeletal muscle insulin signalling 
were impaired.  The opposite has also been reported by Carey and colleagues, whereby the 
effect of IL-6 treatment on insulin signalling was additive to that of insulin (unpublished 
observations).  Chronic IL-6 administration in mice, eliciting levels similar to those found in 
obese individuals, induced hepatic insulin resistance without impairing skeletal muscle insulin 
signalling; suggesting a tissue-specific effect of IL-6 on insulin action in vivo (Klover et al., 
2003).  However, the reverse was found in vitro by Weigert and colleagues, where IL-6 
treatment of human muscle cells induced Akt activation, glycogen synthase kinase-3 
phosphorylation, and glycogen synthesis.  Moreover, these effects were observed  in skeletal 
muscle but not liver tissue (Weigert et al., 2005).  Data of IL-6 treatment in vitro in 
adipocytes is also conflicting with Rotter and colleagues reporting impaired insulin signalling 
(Rotter et al., 2003) and Stouthard and colleagues reporting positive effects additive to those 
of insulin (Stouthard et al., 1996).  IL-6 infusion during a hyperinsulinemic-eyglycemic 
clamp in rodents either decreases (Kim et al., 2004a) or has no effect (Rotter Sopasakis et al., 
2004) on whole body glucose disposal, and recently, Febbraio and colleagues conducted a 4-h 
IL-6 infusion in healthy human subjects, which improved insulin sensitivity and did not 
impair insulin’s ability to suppress hepatic glucose production  (Carey et al in review after 
revision).   
 
Increasing severity of insulin resistance has been associated with intramuscular 
triacylglyceride accumulation (Phillips et al., 1996; Pan et al., 1997; Krssak et al., 1999), 
increased abdominal adiposity, increased intramuscular long-chain acyl-CoA content (Oakes 
et al., 1997a; Oakes et al., 1997b), and alterations in membrane phospholipid fatty acid 
composition (Storlien et al., 1991).  Furthermore, lipid-activated signalling pathways interfere 
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with insulin signal transduction in skeletal muscle to cause insulin resistance (Boden, 1997; 
Dresner et al., 1999; Griffin et al., 1999).  Epidemiological evidence suggests that it is the 
ingestion of saturated rather than unsaturated fat that is closely linked to insulin resistance and 
hyperinsulinemia (Dobbins et al., 2002).  Specific lipids with distinct effects in different cell 
types can influence insulin signalling at different sites.  Moreover, aberrant deposition of lipid 
substrates in skeletal muscle and liver tissue as a result of lipid oversupply contributes to the 
development of insulin resistance (Krebs & Roden, 2005).  Adipose tissue is no longer 
regarded simply as an energy store.  It is now well recognised that adipose tissue is an active 
endocrine organ.  Adipose tissue itself is responsive to central and peripheral metabolic 
signals and is capable of integrating such signals and responding by regulating the secretion 
of multiple adipose-specific or enriched adipokines, which are implicated in the regulation of 
energy homeostasis, innate immune system, and lipid metabolism.  The systemic effects of 
impaired insulin sensitivity associated with obesity may be a reflection of the lipotoxic effects 
of fatty acids (Lelliott & Vidal-Puig, 2004) as well as an imbalance of adipokines (Fantuzzi, 
2005) (Figure 1.2).  
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Figure 1.2  Schematic representation of the major intracellular defects associated with insulin 
resistance which coincide with IL-6 production, 
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Elevated circulating levels of IL-6 are consistently reported to be implicated in causing insulin 
resistance in obese and type 2 diabetic patients (Bastard et al., 2000; Kern et al., 2001; 
Bastard et al., 2002).  It is plausible that IL-6 is elevated in this patient population as a 
consequence of increased fat mass, rather than being associated with insulin resistance per se.  
Consolidating this notion are a few studies, which have dissected IL-6 levels from insulin 
resistance per se.  Levels of IL-6 in obese non-diabetic subjects were shown to correlate with 
percentage body fat and not insulin sensitivity once corrected for body fat levels (Vozarova et 
al., 2001).  Carey and colleagues have also reported that elevated plasma concentrations of 
IL-6 observed in patients with type 2 diabetes and age-matched control subjects are not 
related to insulin sensitivity, but are rather an index of adiposity (Carey et al., 2004).  In vitro 
investigations mentioned in the previous section further support the role of IL-6 in lipid 
metabolism; decreasing intramyocellular fatty acid accumulation.  However, this needs to be 
further investigated in vivo in the context of metabolic disease. 
 
Chronic inflammation in metabolically active tissues such as skeletal muscle, liver and 
adipose tissue, characterised by abnormal production of pro-inflammatory cytokines and 
acute-phase reactants by adipocytes and macrophages, is tightly associated with obesity (Sethi 
& Hotamisligil, 1999).  This observation is consistent with the long held notion that type 2 
diabetes is a chronic low-grade inflammatory disease (Pickup et al., 1997; Pickup & Crook, 
1998).  However, whilst obesity is a major predictor of fulminate type 2 diabetes, there are 
multiple risk factors and obesity alone does not necessarily confer diagnosis, as impaired 
glucose tolerance and insulin sensitivity must also be present.  The literature clearly 
demonstrates that lipids are involved in the induction of insulin resistance, and that adipocytes 
are intricately involved in the control of insulin responsiveness at the whole body level.   
Adipocytes express and release a number of adipokines (eg adiponectin, leptin, resistin, IL-6, 
TNF-α) that have both positive and negative effects on peripheral and central tissues (for 
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review see Rajala & Scherer, 2003).  The adipocyte is a likely candidate for the production 
and release of acute phase reactants as many general transcription factors for the acute-phase 
reactant response are expressed abundantly in the adipocyte (Trayhurn & Wood, 2004) and 
cytokines that are considered to be acute-phase inflammatory markers are correlated with 
markers of the metabolic syndrome (Pickup et al., 1997; Pickup & Crook, 1998; Pickup et al., 
2000a; Pickup et al., 2000b; Rajala & Scherer, 2003).   
 
The pro-inflammatory cytokine tumour necrosis factor alpha (TNF-α) production within and 
release from adipose tissue is associated with obesity.  Weisberg and colleagues have shown 
more specifically, that macrophages within the adipose tissue, rather than adipocytes per se, 
that are responsible for almost all adipose tissue TNF-α production (Weisberg et al., 2003).  
TNF-α promotes insulin resistance in several insulin-responding cells and tissues, inhibits 
tyrosine phosphorylation of IRS-1 and results in a state that is suggestive of type 2 diabetes 
and obesity (Hotamisligil et al., 1993).  Shulman has shown that an increase in intracellular 
FA also elicited this phenomenon (Shulman, 2000).  Furthermore,  neutralization of TNF-α 
improves insulin resistance (Hotamisligil et al., 1993).  In addition to the inhibition of IRS-1 
tyrosine phosphorylation, TNF-α also stimulates IRS-1 serine phosphorylation, which in 
contrast to tyrosine phosphorylation, blunts insulin signalling (Hotamisligil et al., 1996; 
Kanety et al., 1996; Aguirre et al., 2000).  JNK, which serves as a sensing juncture for 
cellular stress and inflammatory status, also phosphorylates IRS-1 serine residues (Hiratani et 
al., 2005).   JNK activity is elevated in the tissues of several obesity models, including high-
fat diet-induced obesity and genetic leptin deficiency (Hirosumi et al., 2002), and its ablation 
in an animal model improves insulin sensitivity and prevents obesity (Hirosumi et al., 2002).  
There is strong evidence to suggest that the disruption of insulin signalling caused by 
cytokines that are considered to be acute-phase inflammatory markers (TNF-α, IL-6) is 
mediated by activation of inhibitor of kappa B kinase β (IκKβ), which removes the inhibitor 
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of kappa B (IκB) protein from its inhibitory site on nuclear factor kappa B (NF-κ B), the major 
inflammatory-mediating transcription factor (Yin et al., 1998; Yuan et al., 2001).  Moreover, 
the fatty acid-induced insulin resistance previously discussed, which is mediated through 
LCACoA and DAG activating JNK and the PKC–theta isozymes, consequently activates 
IκKβ (Perseghin et al., 2003). Since IL-6 is often elevated in type 2 diabetes and its 
production is stimulated by TNF-α (Neta et al., 1992), it was hypothesised that IL-6 might 
contribute to the development of type 2 diabetes (Pickup et al., 1997; Pradhan et al., 2001).  
However, the etiology of IL-6 on these parameters in obesity and insulin resistance are limited 
and this area warrants further investigation.  
 
Recently, a  mouse model of IL-6 deficiency (IL-6-/-) demonstrated increased fat mass, 
mature-onset obesity, leptin resistance and glucose intolerance; characteristics which were 
attenuated with subsequent IL-6 treatment (Wallenius et al., 2002b). Chronic 
intracerebroventricular IL-6 treatment in rats also decreased body weight and fat mass by 
decreasing food intake and stimulating energy expenditure at the level of the central nervous 
system (Wallenius et al., 2002a; Jansson et al., 2003).  Young, pre-obese IL-6-/- mice were 
reported to have diminished AMPK phosphorylation in muscle and adipose tissue, which, 
given the role of AMPK activation in metabolic regulation, may contribute to the developing 
phenotype (Kelly et al., 2004).  In contrast to these studies, Di Gregorio and colleagues 
reported that IL-6-/- mice did not demonstrate obesity, fasting hyperglycemia or abnormal 
lipid metabolism (Di Gregorio et al., 2004).  The mechanisms perturbing glucose tolerance, 
insulin sensitivity and energy regulation in the IL-6-/- mouse remain to be determined. 
 
In summary, the role of IL-6 in the induction of insulin resistance, particularly in insulin 
sensitive tissues is ambiguous.  The direct metabolic effects of IL-6 in the regulation of 
glucose and fatty acid metabolism in skeletal muscle and adipose tissue remain to be clarified.  
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This thesis sought to investigate the biological role of IL-6 in metabolic states of health and 
disease. 
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CHAPTER TWO 
 
 
AIMS OF THE THESIS  
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2.1 Aims of the thesis 
 
The primary aim of this thesis was to determine the role of IL-6 in the regulation of 
metabolism, particularly with respect to its role in a) exercise metabolism and b) insulin 
sensitivity.  Such investigation encompassed the examination of in vivo and in vitro (human 
and animal) models, as well as the execution of a number of analytical techniques. 
 
The expression and release of IL-6 from contracting skeletal muscle was known to be altered 
in metabolically perturbed states.  Affected by exercise mode, intensity, and duration, as well 
as glycogen state, the hypothesis within the literature was that IL-6 was released from skeletal 
muscle during exercise to act in a "hormone-like" manner to increase metabolic substrate 
supply to the muscle.  As adrenaline levels are also altered by these variables and are known 
to regulate lipolysis, the first study (Chapter 3) investigated whether adrenaline per se induced 
IL-6 protein production and or release from skeletal muscle.  After establishing that 
adrenaline was not stimulating IL-6 production, the second study (Chapter 4) investigated the 
affect of the suppression of lipolysis on IL-6 levels during exercise. 
 
The ablation of IL-6 within a whole body system was then investigated in a genetically 
modified mouse model.  The third study (Chapter 5) endeavoured to characterise the 
regulation of fatty acid metabolism and insulin signalling in the IL-6 knockout mouse in the 
basal state as well as in a state of diet-induced insulin resistance.  These parameters were then 
investigated following chronic short-term IL-6 treatment (Chapter 6). 
 
Acute elevations in IL-6 levels with exercise would appear to be associated with beneficial 
effects on metabolism and insulin sensitivity, yet chronically elevated IL-6 levels have been 
associated with negative effects in conditions of obesity and insulin resistance.  Thus, the final 
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study (Chapter 7) investigated whether the mode of IL-6 administration had disparate effects 
on these parameters. 
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CHAPTER THREE  
 
 
 IONOMYCIN, BUT NOT PHYSIOLOGIC DOSES OF 
ADRENALINE, STIMULATES SKELETAL MUSCLE 
INTERLEUKIN-6 MRNA EXPRESSION AND PROTEIN RELEASE 
 27
3.1 Introduction 
 
Interleukin-6 (IL-6) is a multifunctional immune-modulating cytokine that is elevated in 
stressed states and in patient populations.  Expression of IL-6 is putatively associated with 
insulin resistance, visceral obesity, atherosclerosis, and glucocorticoid receptor dysfunction 
(for review see (Febbraio & Pedersen, 2002).  It is not surprising that IL-6 is associated with 
obesity-related disorders as it is released from adipose tissue (Mohamed-Ali et al., 1997) and 
positively correlates with body fat levels (Vozarova et al., 2001; Carey et al., 2004).  Recent 
evidence suggests, however, that IL-6 is produced by contracting skeletal muscle (Febbraio & 
Pedersen, 2002; Pedersen et al., 2003), but the precise mechanism(s) that regulate IL-6 
production by skeletal muscle are unclear.  Of note, skeletal muscle IL-6 mRNA expression is 
not elevated in insulin-resistant humans, nor is it activated by insulin in these patients (Carey 
et al., 2004), suggesting that factors associated with physical exercise and/or muscle 
contraction regulate IL-6 transcription in muscle (Febbraio, 2003).  
 
It is well known that during exercise the increase in plasma adrenaline is marked, and it has 
often been hypothesized that the increase in circulating adrenaline could mediate, in part, the 
IL-6 response (Nehlsen-Cannarella et al., 1997; Nieman et al., 1998; Nieman et al., 2003).  
Indeed, there is evidence to suggest that adrenergic regulation may be important in regulating 
IL-6.  Administration of adrenaline increases plasma IL-6 in both rats (DeRijk et al., 1994) 
and humans (Sondergaard et al., 2000).  Furthermore, plasma adrenaline concentrations 
correlate with plasma IL-6 (Papanicolaou et al., 1996), while the release of IL-6 from skeletal 
muscle has been shown to be positively correlated to exercise intensity and arterial adrenaline 
concentration (Helge et al., 2003) during exercise in humans.  However, these studies do not 
provide evidence that adrenaline increases IL-6 production in skeletal muscle, because they 
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either did not identify the source of the systemic increase when either animals or humans were 
infused at rest, or the present associative data collected during exercise. 
 
In contrast, during exercise, plasma IL-6 increased 30-fold, however, an adrenaline infusion 
mimicking closely the exercise-induced increase in plasma adrenaline increased plasma IL-6 
only 4-fold (Steensberg et al., 2001b), suggesting that during exercise the role of plasma 
adrenaline on the IL-6 response is relatively minor.  In addition, during 2 legged knee 
extensor exercise, both the IL-6 gene transcription and protein release was augmented in a leg 
previously depleted of glycogen, even though both legs were subjected to the same level of 
circulating adrenaline (Steensberg et al., 2001a), also suggesting that factors other than 
adrenaline play a more important role in IL-6 production during contraction.  The direct effect 
of adrenaline on IL-6 gene expression and protein release from skeletal muscle has not been 
experimentally investigated, and this was the primary aim of the present study.  Using an in 
vitro rat skeletal muscle incubation model, we hypothesized that physiologic adrenaline 
would neither result in an increase in IL-6 mRNA nor protein release from these muscles. 
 
The rapid increase in IL-6 nuclear transcription rate seen within the first 30 min of exercise 
has been proposed to be attributable to cytosolic calcium (Ca2+) levels (Keller et al., 2001).  
The role of intracellular Ca2+ ([Ca2+]i) in the control of a diverse range of cellular functions, 
including gene expression and proliferation, is well documented (Berridge, 1993; Ghosh & 
Greenberg, 1995) and the [Ca2+]i concentration has been implicated in signalling cascades as a 
potent signalling factor for IL-6 transcription (Febbraio & Pedersen, 2002; Febbraio, 2003).  
Indeed, it has been demonstrated that the calcium ionophore, ionomycin, can increase IL-6 
gene expression in cultured human primary muscle cells after a 6-hour incubation period, and 
further so by 48 hours (Keller, 2002).  The effect of Ca2+ stimulation on IL-6 expression has 
only been investigated under such long-term circumstances, and whether this response has a 
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more rapid effect, or whether ionomycin treatment results in IL-6 protein release has not been 
investigated.  This was the secondary aim of this study, and we hypothesized that ionomycin 
administration would result in IL-6 gene transcription in, and protein release from, skeletal 
muscle. 
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3.2  Methods 
 
Animals and muscle preparation.  Male Sprague-Dawley rats of 4 weeks of age and 85 ± 3 g 
body weight were purchased from Monash Medical Centre (Clayton, Victoria, Australia).  
The animals were housed in the RMIT University animal facility in a controlled environment 
with a 12:12 hour light:dark cycle and fed rat chow and water ad libitum.  All experimental 
procedures were approved by the Animal Experimentation Ethics Committee of RMIT 
University (AEEC # 0313).  Rats were anesthetized with an intraperitoneal injection of 
pentobarbital sodium (6 mg·100g–1 body weight, Nembutal; Rhone Merieux, Queensland, 
Australia), and the soleus muscle from both hind limbs were excised from tendon to tendon.  
Care was taken to avoid damage to the muscle during surgery, and animals were immediately 
euthanized with an overdose of Nembutal. 
 
Muscle metabolite experiments.  Viability of our soleus muscle preparation was established in 
a preliminary experiment. Paired muscles were isolated as described.  To determine the 
viability of the muscle over the incubation period, 1 muscle was rapidly frozen, whereas the 
contralateral muscle was incubated for 60 min in gassed Krebs buffer (see below for details), 
then snap-frozen in liquid nitrogen.  Muscles were freeze-dried and powdered, and non-
muscle contaminants were removed.  The freeze-dried muscle was extracted in 0.5 mol/L 
HClO4 (1 mmol/L EDTA) and neutralized with 2.2 mol/L KHCO3.  Adenosine triphosphate 
(ATP), phosphocreatine (PCr), creatine, and lactate were subsequently determined by 
spectrophotometric assays (Harris et al., 1974; Passonneau & Lauderdale, 1974).  
 
Experimental protocol.  Each intact muscle was preincubated in a 20-mL vial containing 3 
mL pregassed (95 % O2, 5 % CO2) Krebs buffer (8 mmol/L glucose) for 10 min at 30 °C.  
After preincubation, either Krebs buffer (CON, n = 5), 10 µmol/L ionomycin (IONO, n = 5), 
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or adrenaline at concentrations of 1,000 (ADR 1,000, n = 8), 100 (ADR 100, n = 7), and 10 
nmol/L (ADR 10, n = 9) was added to the appropriate vial and incubated for a further 40 min.  
All adrenaline stock solutions were prepared in Krebs buffer with 2 mg/mL ascorbic acid to 
prevent oxidation.  A 3 mmol/L stock solution of adrenaline bitartrate (AstraZeneca, North 
Ryde, NSW, Australia) was diluted to 3 µmol/L daily such that the appropriate volume could 
be added to the bath to achieve concentrations of 10, 100, or 1,000 nmol/L ADR in a final 
bath volume of 3.0 mL.  The total volume added for all conditions was 100 µL. At the end of 
the incubation, muscles were snap-frozen in liquid nitrogen and stored at –80°C for later 
analysis.  A 1 mL aliquot of incubation media was also removed and stored at –80°C for later 
analysis. 
 
Determination of IL-6 gene expression and protein release.  The soleus muscle was extracted 
for total RNA using the acid guanidinium thiocyanate-phenol-chloroform extraction of 
Chomczynski and Sacchi (Chomczynski & Sacchi, 1987), modified as previously described 
(Febbraio & Koukoulas, 2000).  Samples were reverse transcribed using Taqman Reverse 
Transcription reagents (Applied Biosystems, Foster City, CA, USA) at a final concentration 
of 10 ng/µl.  PCR reactions were completed with individual reactions of 5 µg total RNA, 1 x 
Bio-Rad iQ Supermix ((Bio-Rad, Hercules, CA, USA), 200 nM Taqman fluorescent probe 
(Applied Biosystems) and 900 nM PCR primer (Sigma Genosys, Castle Hill, NSW, Australia) 
in a total volume of 25 µl using a Bio-Rad iCycler (Bio-Rad).  Primer and Taqman probe 
were designed using Primer Express software (Applied Biosystems) to appropriate 
specifications from the rat IL-6 mRNA sequence (GenBank/EMBL Accession No. M26744).  
An 81-bp IL-6 gene fragment was amplified using the forward primer 5´-
ATATGTTCTCAGGGAGATCTTGGAA-3´ and reverse primer 5´-
GTGCATCATCGCTGTTCATACA-3´ (Sigma Geno-sys, Castle Hill, NSW, Austraila).  
Probes were designed with the FAM (6-carboxyflourescein) reporter dye on the 5’ end and 
 32
TAMRA (6-carboxy-tetramethylrhodamine) quencher dye to the 3’ end.  18S mRNA was also 
amplified, and the TaqMan probes and primers for this gene were supplied in a control reagent 
kit (Applied Biosystems).  Gene expression was quantified with a multiplex comparative 
critical threshold (CT) method (Bio-Rad iCycler IQTM, Hercules, CA).  The cycle number at 
which the cDNA amplification is first detected is reflected by the CT value.  For each sample, 
a change ( ) in CT value was obtained by subtracting 18S CT from IL-6 CT.  A – CT value 
was obtained by subtracting the intervention value from the control value.  The expression of 
rodent IL-6 was then evaluated by 2– – CT.  The IL-6 protein released from the muscle into 
the incubation media was quantified by enzyme-linked immunosorbent assay (ELISA) 
(Quantikine; R&D Systems, Minneapolis, MN). 
 
Statistical analysis.  Comparisons between means were made using the paired t test.  A P 
value of less than 0.05 defined statistical significance.  All values are presented as mean ± 
SEM. 
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3.3 Results 
 
Isolated muscles were viable over the 60 min incubation period as indicated by the 
maintenance of ATP and total creatine within the muscle (rapid freeze: 15.9 ± 0.7 and 82.2 ± 
5.6; postincubation: 18.4 ± 3.0 and 90.6 ± 3.9 mmol·kg–1dm, respectively).  IL-6 mRNA was 
increased by IONO and pharmacologic levels of ADR (1,000 nmol/L; P < 0.05) compared 
with CON.  Lower levels of ADR (10 and 100 nmol/L) were without effect on IL-6 mRNA 
(Fig 3.1, upper).  IL-6 protein increased (P < 0.05) in the incubation media with IONO 
compared with CON.  Despite the observed increase in IL-6 mRNA with pharmacologic 
ADR, there was no measurable increase in IL-6 protein in the incubation media with ADR at 
all concentrations (Fig 3.1 lower). 
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Figure 3.1  IL-6 mRNA expression (upper) in and release (lower) from rat soleus muscle 
incubated for 60 min in saline (control, n = 5), 10 µmol/L ionomycin (IONO, n = 5), 1,000 
nmol/L adrenaline (ADR 1,000, n = 8), 100 nmol/L adrenaline (ADR 100, n = 7), 10 nmol/L 
adrenaline (ADR 10, n = 9).  *Indicates difference (P < 0.05) from control.  Data are 
expressed as mean ± SEM.  
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3.4 Discussion 
 
This is the first study to investigate the direct effect of adrenaline on IL-6 gene expression 
within, and protein release from, skeletal muscle.  In the present study, IL-6 mRNA was not 
altered by short-term exposure to high physiologic and supra-physiologic adrenaline 
concentrations, whereas adrenaline, at a concentration of more than 1,000 times that occurring 
physiologically, while increasing IL-6 mRNA, did not increase IL-6 protein release.  These 
data indicate that adrenaline is unlikely to be the stimulus for the exercise-induced increase in 
IL-6 gene expression and does not increase IL-6 protein release from skeletal muscle. 
 
Helge and colleagues (Helge et al., 2003) correlated plasma IL-6, released from skeletal 
muscle during exercise, with arterial adrenaline concentrations, and Nieman and colleagues 
(Nieman et al., 2003) suggested that during a prolonged exercise bout differences in IL-6 
gene expression were due to differences in blood adrenaline levels.  Previous studies have 
investigated the effect of adrenaline infusion on IL-6 levels.  DeRijk and colleagues (DeRijk 
et al., 1994) infused adrenaline to physiologic concentrations and observed an increase in 
plasma IL-6, and in the face of a 24-fold increase in adrenaline concentration Søndergaard 
and colleagues (Sondergaard et al., 2000) saw a 2-fold to 3-fold increase in plasma IL-6.  
These studies have reported measurements of circulating factors and have not isolated the 
impact of adrenaline on skeletal muscle IL-6 per se.  Based on our present data it appears, 
therefore, that in the studies mentioned above, the source of the IL-6 was not the skeletal 
muscle.  It must be noted, however, that in the present study we investigated the effects of 
adrenaline per se on the IL-6 response in muscle and did not excise muscle from animals 
following contraction.  Thus, we cannot rule out the possibility that following exercise the 
relationship between adrenaline and IL-6 may differ, because the high-energy phosphagen 
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content of contracting compared with non-contracting muscle may differ markedly, and this 
may affect the response to adrenaline. 
 
It is well known that intracellular calcium ([Ca2+]i) controls a diverse range of cellular 
functions including gene expression and proliferation, and the literature suggests that [Ca2+]i 
is a potent signalling factor for IL-6 transcription  (Keller et al., 2002).  Our finding that the 
Ca2+ ionophore, ionomycin, increased the IL-6 gene expression is consistent with previous 
findings (Keller et al., 2002).  Keller and colleagues incubated isolated human muscle cells 
with ionomycin and reported progressive increases in IL-6 mRNA from 6 to 48 hours of 
incubation.  In the present study, we extended on their findings and demonstrated increased 
IL-6 gene expression within 1 hour.  Moreover, these data demonstrate that Ca2+ increases IL-
6 protein release from skeletal muscle.  The present finding showing that the Ca2+ ionophore 
ionomycin increases IL-6 protein release from skeletal muscle is consistent with marked 
increases in IL-6 protein release seen within 30 min of exercise (Febbraio et al., 2003c), 
which coincides with a period when there is a rapid increase in cytosolic Ca2+ levels due to 
mechanical load (Obici & Rossetti, 2003).  Ca2+ signals are known to propagate to the nucleus 
where they activate or inhibit the function of various transcription factors, and hence, 
influence gene transcription.  Some of the signals downstream of Ca2+ have been identified as 
activators of cytokine gene transcription (Febbraio & Pedersen, 2002), but the degree to 
which IL-6 is activated in skeletal muscle by such signalling pathways is not known. 
 
It is noteworthy, that while IONO increased both IL-6 mRNA and protein release, ADR 
1,000, did not result in protein release (Figure 3.1, lower), despite the fact that the mRNA 
increase was marked (Figure 3.1 upper).  It is difficult to interpret these results, however, the 
dose of adrenaline in these circumstances was pharmacologic, and the stimulus for IL-6 
mRNA transcription may have been different compared with IONO, resulting in 
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posttranscriptional modification.  Alternatively, the release of IL-6 may have been impaired 
under these circumstances. 
 
In conclusion, we have demonstrated for the first time that calcium stimulates IL-6 gene 
expression within, and protein release from skeletal muscle, but that physiologic 
concentrations of adrenaline do not stimulate IL-6 gene expression within or protein release 
from rat soleus muscle in vitro. 
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CHAPTER FOUR 
 
 
  SUPPRESSING LIPOLYSIS INCREASES INTERLEUKIN-6 AT 
REST AND DURING PROLONGED MODERATE-INTENSITY 
EXERCISE IN HUMANS 
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4.1 Introduction 
 
Interleukin (IL)-6 is released from adipose tissue under non-inflammatory conditions, 
contributing 30% of the circulating IL-6 levels at rest (Mohamed-Ali et al., 1997), which is 
exacerbated after exercise (Keller et al., 2003a).  Recent work has demonstrated that IL-6 is 
released from skeletal muscle during exercise (for review, (Febbraio & Pedersen, 2002).  
Specifically, the net leg release of IL-6 can account for the majority of the marked elevation 
of systemic IL-6 observed during exercise (Steensberg et al., 2000). Moreover, this release is 
potentiated by low-intramuscular glycogen stores (Steensberg et al., 2001a) and is markedly 
attenuated when subjects are fed glucose throughout exercise (Febbraio et al., 2003b). In 
circumstances in which muscle glycogen is low, the reliance on fatty acids as a fuel source is 
altered, and, therefore, these studies may suggest that one metabolic role of muscle-derived 
IL-6 is to act on adipose tissue to increase lipolysis, thereby providing an extracellular 
substrate. Two recent studies have demonstrated that recombinant human IL-6 infusion 
enhances lipolysis. Van Hall and colleagues (van Hall et al., 2003) demonstrated that IL-6 
infusion into healthy subjects increased adipose tissue lipolysis and increased fat oxidation in 
the absence of changes in other lipolytic hormones. In addition, Lyngsø and colleagues 
(Lyngso et al., 2002b) showed that IL-6 infusion gave rise to an increase in net glycerol 
release in subcutaneous adipose tissue, leading these authors to conclude that IL-6 elicits 
lipolytic effects in human adipose tissue in vivo. Further research from transgenic mice studies 
also suggests that IL-6 is a lipolytic cytokine (Wallenius et al., 2002b).  
 
The exercise-induced increase of IL-6 has been hypothesized to have an energy-sensitizing 
role, sensing metabolically demanding situations, whereby it is released from contracting 
skeletal muscle to act in a hormone-like manner, mobilizing extracellular substrates, and/or 
augmenting substrate delivery during exercise (Pedersen et al., 2001; Febbraio & Pedersen, 
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2002). To further investigate this potential role of IL-6 in relation to fat metabolism, in the 
present study, we tested the hypothesis that acute suppression of plasma free fatty acid (FFA) 
levels would augment IL-6 mRNA expression in muscle and adipose tissue and increase the 
plasma concentration of IL-6 in the circulation at rest and during prolonged moderate-
intensity exercise.  
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4.2 Methods 
 
Resting Experiments  
Subject characteristics.   Five healthy, young men (28.8 ± 2.7 yr, 185.0 ± 3.7 cm, 76.3 ± 2.1 
kg, means ± SEM) volunteered to participate in this study, which was approved by the RMIT 
Human Research Ethics Committee.  All subjects were informed of the experimental protocol, 
and the possible associated risks of the study were explained to subjects, both orally and in 
writing, before written, informed consent was obtained.  No subject was taking any 
medication or had any confounding medical history. 
  
Experimental protocol.  Subjects reported to the laboratory in the morning after a 10- to 12-h 
overnight fast and rested quietly.  An indwelling cannula was inserted into an antecubital vein 
for blood sampling and was kept patent by periodic saline infusion.  A resting blood sample 
was taken for analysis of FFA, IL-6, adrenaline, and growth hormone (GH) (as described 
below).  Subjects initially ingested a 10 mg/kg dose of nicotinic acid (NA; 250 mg tablets; 
Aspen Pharmacare) (time = 0 min), followed by three subsequent doses of 5 mg/kg at 30 min 
intervals. Additional blood samples were obtained at 60 and 120 min. Muscle and adipose 
tissue were not sampled in this resting component of the study.  All subjects experienced the 
expected side effects of NA ingestion, which included flushing (a reddening of the skin due to 
peripheral vasodilation over most of the body), a sensation of heat, and a tingling sensation, 
which started 15–20 min after the first dose.  No subjects experienced stomach or 
gastrointestinal upset.  
 
Exercise Experiments  
Subject characteristics.  Seven active men (24.3 ± 2.9 yr, 185.2 ± 2.2 cm, 80.4 ± 3.4 kg, 
means ± SE) volunteered to participate in this study, which was approved by the RMIT 
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Human Research Ethics Committee, in accordance with the Declaration of Helsinki.  All 
subjects were informed of the experimental protocol, and the possible associated risks of the 
study were explained to subjects both orally and in writing before written, informed consent 
was obtained.  No subject was taking any medication or had any confounding medical history.  
 
Pre-experimental procedures.  Subjects visited the laboratory on four occasions.  On the first, 
they performed a continuous and incremental workload test to exhaustion on an electrically 
braked cycle ergometer (LODE Instrument, Groningen, The Netherlands) to determine their 
peak pulmonary oxygen uptake ( O2 peak), which averaged 4.3 ± 0.3 L/min.  Subjects returned 
to the laboratory 1 week later to complete a familiarization trial that consisted of cycling at 
60% O2 peak for 120 min with NA ingestion (described subsequently).  Tissue sampling did 
not occur during this trial, but subjects' response to NA was monitored.  Expired pulmonary 
gases (Quark b2, COSMED, Rome, Italy) were collected and analyzed online at 30-min 
intervals. The purposes of the practice ride were to familiarize the subject with the protocol, 
confirm the subject's tolerance to oral NA supplementation, and confirm the exercise power 
output of 60% O2 peak.  The absolute power output for the trials was 156 ± 5 W.  
 
Experimental protocol.  Each subject performed two experimental trials, separated by at least 
7 days. For the day preceding each trial, subjects were provided with a food parcel [14 MJ, 
80% carbohydrates (CHO)] and were required to abstain from exercise, caffeine, and alcohol.  
Subjects were also instructed to consume 5 ml/kg of tap water on waking to ensure 
euhydration. Subjects reported to the laboratory in the morning after a 10- to 12-h overnight 
fast and rested quietly.  An indwelling cannula was inserted into an antecubital vein, as 
described above.  Three incisions were made through the skin and fascia over the vastus 
lateralis muscle of one leg, and one incision was made in the ventrolateral abdominal wall, 
10 cm lateral of the navel under local anaesthesia (2% lidocaine), for subsequent percutaneous 
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muscle and adipose tissue biopsy sampling, respectively.  Trials were randomized, with 
subjects consuming either NA (described below) or nothing (Con) during the 60 min before 
exercise.  Due to the mild side effects of NA (described above), we could not disguise the 
treatment, and, therefore, it was of no benefit to consume a placebo capsule during Con.  
Blood samples were obtained immediately before NA supplementation (–60 min), 
immediately before the start of exercise (0 min), and at 30, 60, 90, 120, 150, and 180 min 
during the exercise protocol.  Immediately before exercise, resting muscle and adipose tissue 
biopsies were obtained while subjects rested on a bed.  Samples were immediately frozen in 
liquid nitrogen and stored until analysis.  Subjects subsequently moved to the cycle ergometer 
and, after a 5-min warm-up at 100 W, commenced cycling at the predetermined workload.  
Subjects ingested 100 ml of water every 60 min to ensure hydration.  Additional muscle and 
adipose tissue samples were obtained at 90 and 180 min of exercise while subjects remained 
on the cycle ergometer.  The elapsed time between cessation of exercise for biopsy sampling 
and resumption of exercise was < 30-sec.  Expired pulmonary gases were collected at 30-min 
intervals for the measurement of expired fractions of O2, CO2, and ventilation.  All trials were 
performed at an ambient temperature of 19 – 21°C.  During the NA trial, subjects ingested a 
total of 45 mg/kg NA over eight individual doses: 10 mg/kg 60 min before exercise, 5 mg/kg 
30 min before (–30) and immediately before (0 min) exercise, and at 30-min intervals 
throughout exercise.  
 
Fat and carbohydrate oxidation.  Whole body CHO and fat oxidation rates were calculated 
from each period of gas collection and estimated by using stoichiometric equations (Peronnet 
& Massicotte, 1991).  
 
Blood metabolites and hormonal analyses.  Venous blood was placed into precooled tubes 
containing EDTA for IL-6, growth hormone (GH), and cortisol analysis.  IL-6 was analysed 
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by commercially available enzyme-linked immunosorbent assay (Qunatikine high sensitivity 
hIL-6 ELISA; R&D Systems Europe, Oxon, UK), and GH and cortisol were analysed by 
radioimmunoassay (Coat-a-Count, Diagnostic Products).  Five milliliters of whole blood were 
placed into pre-cooled tubes containing lithium heparin for FFA, insulin, glucose, and lactate 
analysis.  FFA was analysed by an enzymatic colorimetric method (NEFA C, Wako 
Chemicals), and insulin was analysed by radioimmunoassay (Coat-a-Count, Diagnostic 
Products).  Glucose and lactate were immediately analysed by an automated method (Yellow 
Springs Instruments 2300 STAT).  Samples for adrenaline determination were treated with 
EGTA/GSH and later analysed by radioimmunoassay (LDN, Nordhorn, Germany).  All tubes 
were immediately spun at 1,300 rpm at 4°C for 3 min, and plasma was recovered and stored at 
–80°C for the respective analysis.  
 
Muscle glycogen content.  Muscle samples were freeze-dried and then powdered so as to be 
able to separate and remove all non-muscle tissue such as connective tissue and fat.  Samples 
were extracted in 250 µl of 2 M HCl at 100 °C for 2 h and then neutralized with 750 µl of 
0.667 M NaOH.  The extract was then analysed for glucose, with the absorbance at 340 nm 
determined before and after addition of 1 µg of hexokinase (Passonneau & Lauderdale, 1974).  
Glycogen content was expressed as micromoles of glucosyl units per milligram of dry tissue. 
 
Muscle and adipose tissue IL-6 mRNA analyses.  Muscle and adipose tissue samples were 
extracted for total RNA by using the acid guanidium thiocyanate-phenol-chloroform 
extraction of Chomczynski and Sacchi (Chomczynski & Sacchi, 1987), modified as 
previously described (Febbraio & Koukoulas, 2000).  IL-6 mRNA expression was determined 
on these samples by real-time PCR, as previously described (Starkie et al., 2001a).  IL-6 
probe and primers were designed from the human IL-6 gene sequences (GenBank/EBML 
accession nos. M54894 and M38669).  An 81-base pair IL-6 fragment was amplified by using 
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the forward primer 5'-GGTACATCCTCGACGGCATCT-3' and reverse primer 5'-
GTGCCTCTTTGCTGCTTTCAC-3' (Sigma Geno-sys, Castle Hill, NSW, Australia).  A 
TaqMan fluorescent probe, 5'-FAM (6-carboxyfluorescein)-
TGTTACTCTTGTTACATGTCTCCTTTCTCAGGGCT-3' TAMRA (6-carboxy-
tetramethylrhodamine) (Applied Biosystems), was included with the primers in each reaction. 
18S mRNA was also amplified, and the TaqMan probes and primers for this gene were 
supplied in a control reagent kit (Applied Biosystems).  Gene expression was quantified with a 
multiplex comparative critical threshold (CT) method (Bio-Rad i Cycler IQTM, Hercules, 
CA).  The cycle number at which the cDNA amplification is first detected is reflected by the 
CT value.  For each sample, a change ( ) in CT value was obtained by subtracting 18S CT 
from IL-6 CT with the resting value as the control.  Resting values for each subject were 
subtracted from the exercise samples for each subject to derive a – CT value.  The 
expression of human IL-6 was then evaluated by 2– – CT.  
 
Statistical analysis.  A one-way ANOVA with repeated measures (time) was performed on the 
resting data.  Statistical analysis for the exercise study was performed by two-way ANOVA 
with repeated measures (time x trial), and specific differences were identified by using a 
Student-Newman-Keuls post hoc procedure.  Statistical significance was set at P 0.05.  Data 
are expressed as means ± SEM.  
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4.3 Results   
 
Resting Experiments 
Plasma FFAs, adrenaline, and IL-6 response.  The plasma FFA concentration was reduced 
over the 120 min of NA ingestion (0 min: 0.26 ± 0.5 mM; 120 min: 0.09 ± 0.02 mM; P < 
0.002), whereas the plasma IL-6 concomitantly increased approximately eightfold (0 min: 
0.75 ± 0.18 pg/ml; 120 min: 6.05 ± 0.89 pg/ml; P < 0.001) (Figure 4.1).  Small increases were 
observed for plasma adrenaline (0 min: 0.22 ± 0.01 nM; 120 min: 0.33 ± 0.02 nM; P < 0.05) 
and GH (0 min: 0.39 ± 0.04 µg / mL; 60 min: 0.64 ± 0.04 µg / mL; P < 0.05).  
 
Figure 4.1  Plasma free fatty acid (FFA; A) and IL-6 (B) concentration before (0 min) and 
after (60 and 120 min) nicotinic acid ingestion.  Values are means ± SE (n = 5).  *Different 
from rest, P < 0.05. 
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Table 4.1  Whole body carbohydrate and fat oxidation during 180-min cycling exercise at 62 
± 5% O2peak with or without nicotinic acid ingestion.  
 
Time, min Exercise 
Trial  
30 
 
60 
 
90 
 
120 
 
150 
 
180 
 
Fat oxidation, kJ/min 
Con 13.1 ± 1.7 14.9 ± 2.2 16.3 ± 3.3 22.1 ± 2.1 26.3 ± 3.1 22.8 ± 3.9* 
NA 10.1 ± 1.8 13.8 ± 1.4 12.8 ± 2.3 18.6 ± 5.6 16.3 ± 8.4 16.0 ± 0.5† 
 
Carbohydrate oxidation, kJ/min 
Con 40.3 ± 2.4 37.4 ± 2.6 37.4 ± 2.2 32.6 ± 2.3 33.3 ± 4.5 34.1 ± 3.8 
NA 41.7 ± 2.0 39.3 ± 1.3 42.6 ± 2.9 40.3 ± 5.8 44.1 ± 7.6 55.9 ± 5.4*† 
 
 
Values are means ± SEM; n = 7. O2peak, peak oxygen uptake; Con, control; NA, nicotinic acid.  
* Significant difference from 0 min (P < 0.05).  
  Significant difference from Con (P < 0.05). 
 
Exercise Experiments  
Respiratory responses during exercise.   In both trials, oxygen uptake was initially 57 ± 3% of 
maximal oxygen uptake and increased (P < 0.05) to 67 ± 5% of O2 peak during the last 60 min 
of exercise.  The perceived rate of exertion and ventilation also increased (P < 0.05) late in 
exercise (data not shown) and were not different between trials.  Whole body CHO oxidation 
was lower (P < 0.05) and fat oxidation higher (P < 0.05) throughout exercise in Con compared 
with NA (Table 4.1).  
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Plasma hormone metabolite and IL-6 responses.  Plasma FFA concentrations were not 
different when comparing trials before drug administration.  However, consistent with our 
basal experiment, plasma FFA concentration was reduced (P < 0.05) after 60 min of rest (0 
min) in NA compared with Con.  In Con, plasma FFA increased (P < 0.05) during exercise, 
but this was completely suppressed (P < 0.05) by NA ingestion, such that values throughout 
exercise were lower (P < 0.05) in NA compared with Con (Figure 4.2 A).  Plasma IL-6 was 
not different at rest, and there was a tendency (P = 0.09) for it to increase at rest after NA 
treatment.  Although plasma IL-6 concentration increased (P < 0.001) throughout exercise in 
both trials, the increase was augmented (P < 0.05) throughout exercise in NA (Figure 4.2 B).  
 
Plasma glucose concentration was elevated (P < 0.05) at 0 min in NA compared with Con, 
decreased (P < 0.05) in both trials late in exercise, and was lower (P < 0.05) in NA at 180 min 
compared with Con (Table 4.2).  Plasma lactate was increased (P < 0.05) from resting levels 
late in exercise, and there was no difference between trials (Table 4.2).  Plasma insulin 
concentration decreased (P < 0.05) during exercise in both trials, but there were no differences 
when comparing trials (Figure 4.3 A).  Both plasma adrenaline (Figure 4.3 B) and GH (Figure 
4.3 C) increased (P < 0.05) during exercise in both trials.  However, these increases were 
exacerbated (P < 0.05) in NA compared with Con after 180 min.  Plasma cortisol was not 
significantly affected by exercise in either trial.  However, after 180 min, plasma cortisol was 
higher (P < 0.05) in NA compared with Con (Figure 4.3 D).  
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Figure 4.2  Plasma FFA (A) and IL-6 (B) concentration before (–60, –30, 0 min) and during 
(subsequent time points) 180-min cycling exercise at 62 ± 5% peak pulmonary oxygen uptake 
( O2 peak) with ( ) or without ( ) nicotinic acid ingestion. Values are means ± SEM (n = 7). 
*Different from control (Con), P < 0.05. 
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Table 4.2  Plasma glucose and lactate concentration during 180-min cycling exercise at 62 ± 
5% O2peak with or without nicotinic acid ingestion  
Time, min 
Exercise 
Trial  -60 
 
0 
 
30 
 
60 
 
90 
 
120 
 
150 
 
180 
 
Glucose, mM 
Con  5.4 ± 0.1 5.3 ± 0.1 5.1 ± 0.1 5.1 ± 0.1 4.7 ± 0.1 4.6 ± 0.1 4.5 ± 0.1* 
NA 5.4 ± 0.1 6.0 ± 0.1† 5.2 ± 0.1 5.1 ± 0.1 5.0 ± 0.1 4.6 ± 0.2 4.2 ± 0.2 3.8 ± 0.1*† 
 
Lactate, mM 
Con  1.3 ± 0.2 2.4 ± 0.4 1.8 ± 0.3 1.8 ± 0.4 2.0 ± 0.3 2.0 ± 0.2 2.5 ± 0.2* 
NA 1.1 ± 0.1 1.8 ± 0.3 2.6 ± 0.4 2.1 ± 0.5 2.0 ± 0.3 2.3 ± 0.3 2.7 ± 0.3 3.0 ± 0.3* 
 
Values are means ± SEM; n = 7.  
* Significant difference from 0 min (P < 0.05).  
  Significant difference from Con (P < 0.05). 
 51
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3  Plasma insulin (A), adrenaline (B), growth hormone (C), and cortisol (D) before 
(0 min) and during (90 and 180 min) 180-min cycling exercise at 62 ± 5% O2 peak with ( ) or 
without ( ) nicotinic acid ingestion.  Values are means ± SE (n = 7). *Different from Con (P 
< 0.05). 
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Figure 4.4  Muscle glycogen concentration before (0 min) and during (90 and 180 min) 180-
min cycling exercise at 62 ± 5% O2 peak with (solid bars) or without (open bars) nicotinic acid 
ingestion. Values are means ± SEM (n = 7). dm, dry tissue mass. 
 
 
Intramuscular glycogen and IL-6 gene expression in muscle and adipose tissue. 
Intramuscular glycogen content was not different when comparing the exercise trials at rest.  
Whereas intramuscular glycogen decreased (P < 0.05) during exercise in both trials, there 
were no significant differences either at 90 or 180 min when comparing NA with Con (Figure 
4.4). 
 
Skeletal muscle IL-6 mRNA increased (P < 0.01) in both trials throughout exercise.  In the 
NA trial, skeletal muscle IL-6 mRNA was elevated two- to threefold above Con levels at 180 
min, but this did not reach statistical significance (P = 0.10) (Figure 4.5).  Adipose tissue IL-6 
mRNA increased (P < 0.001) in both trials throughout exercise and was approximately sixfold 
higher (P < 0.01) in NA compared with Con at 180 min (Figure 4.5).  Biopsy samples were 
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not obtained in the resting NA trial.  However, comparison of the resting samples from Con in 
the exercise trial with the resting NA exercise trial samples (1 h after NA ingestion) revealed 
no differences in the parameters measured.  
 
 
 
 
Figure 4.5  IL-6 mRNA expression in skeletal muscle (A) and adipose tissue (B) before (0 
min) and during (90 and 180 min) 180-min cycling exercise at 62 ± 5% O2 peak with (solid 
bars) or without (open bars) nicotinic acid ingestion.  Values are means ± SE (n = 6). 
*Different from Con, P < 0.05. 
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4.4 Discussion  
 
These results demonstrate that circulating IL-6 is elevated in response to acute suppression of 
FFAs, both at rest and during prolonged moderate-intensity exercise.   Furthermore, a 
reduction in plasma FFA availability induced marked increases in adipose tissue IL-6 mRNA.  
We interpret these data to suggest that IL-6 may be released from metabolically active tissues 
in response to reduced FFA in the circulation.  
 
Previous studies have demonstrated strong associations between IL-6 and lipolytic processes.   
Infusion of IL-6 into rats elicited a dose-dependent increase in serum FFA levels (Nonogaki et 
al., 1995), and elevated plasma FFA were reported in cancer patients receiving 
pharmacological recombinant IL-6 infusion (Stouthard et al., 1995); however, a direct 
lipolytic effect of IL-6 could not be ascribed because adrenaline, a lipolytic hormone, was 
concomitantly elevated.  Wallenius et al. (Wallenius et al., 2002b) demonstrated that IL-6–/– 
mice have an increased energy intake and develop mature onset obesity, displaying a rapid 
increase in body fat compared with control mice.  Importantly, fat mass was decreased in IL-
6–/– mice treated with IL-6, without reducing food intake, an effect that was not observed in 
wild-type mice.  Whereas these studies infer a lipolytic role for IL-6, a recent study using 
tracer isotope methodology clearly demonstrated increased adipose tissue lipolysis and 
increased fat oxidation during IL-6 infusion in the absence of changes in anti-lipolytic 
(insulin) and lipolytic hormones (adrenaline, or cortisol) (van Hall et al., 2003).  Hence, one 
biological role of IL-6 may be to increase lipolysis, albeit a relatively modest effect compared 
with the potent effects of insulin and adrenaline on lipolysis.  
 
IL-6 is secreted by adipose tissue in resting conditions (Mohamed-Ali et al., 1997; Orban et 
al., 1999), accounting for 30% of the circulating IL-6 (Mohamed-Ali et al., 1997), and IL-6 
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mRNA expression is increased in adipose tissue during (Keller et al., 2003b)and following 
(Keller et al., 2001) exercise.  Consistent with previous studies (Keller et al., 2003b), we 
demonstrated a marked ( 50-fold) increased in adipose tissue IL-6 mRNA expression during 
exercise in Con.  However, this increase was markedly augmented in NA (Figure 4.2). There 
are two possibilities to explain this observation.  First, IL-6 infusion has been demonstrated to 
increase adipose tissue IL-6 mRNA (Keller et al., 2001).  It is possible, therefore, that NA 
may have increased IL-6 release from other tissues with the subsequent increase in circulating 
IL-6 acting on adipocytes in this manner.  Second, the adipocytes may have increased IL-6 
gene expression as a direct effect of NA and/or secondary to NA-induced reduced lipolysis.  
From our data, we are unable to determine which of these possibilities is likely to have 
occurred.  
 
In the present study, we were unable to determine the source of the increase in circulating IL-
6 with NA, because we did not measure arteriovenous differences across adipose tissue, 
contracting skeletal muscle, or other potential IL-6-releasing tissues.  In normal 
circumstances, the net release of IL-6 from the contracting skeletal muscle can account for the 
majority of the circulating plasma IL-6 (Steensberg et al., 2000).  IL-6 protein is produced 
neither by monocytes (Starkie et al., 2001b) nor hepatosplanchnic viscera (Febbraio et al., 
2003a), but a small amount of IL-6 is released from the peritendon (Langberg et al., 2002) and 
brain (Nybo et al., 2002).  Of note, during a standard exercise bout (1-h two-legged bicycle 
exercise at 60% oxygen uptake), the adipose tissue does not release IL-6 (Lyngso et al., 
2002a).  However, given the profound effects of NA on IL-6 mRNA in adipose tissue, we 
cannot rule out the possibility that the adipose tissue contributed to the approximately two-
fold increase in circulating IL-6 during exercise.  Notwithstanding this, the fact that IL-6 
mRNA tended to be higher in NA and that the contracting limb is the major source of the 
contraction-induced increase in plasma IL-6, our data suggest that the increase in plasma IL-6 
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with NA was due to a increase in net leg release of IL-6 during NA.  Further investigation 
using arteriovenous balance methodology is required to determine the IL-6 release across the 
working leg and adipose tissue with NA at rest and during exercise.  
 
Although NA had no effect on insulin, it increased adrenaline and GH during both the resting 
and exercise experiments, whereas cortisol was increased during exercise.  One cannot 
categorically rule out the possibility, therefore, that the effects of NA on the hormonal milieu 
mediated the changes in IL-6.  It has recently been suggested (Jensen, 2003) that the lipolytic 
action of IL-6 during human in vivo studies (Lyngso et al., 2002a; van Hall et al., 2003) may 
be mediated by increases in GH.  This is entirely plausible because IL-6 often (Swolin & 
Ohlsson, 1996; Tseng et al., 1997; Uronen-Hansson et al., 2003), but not always (Sesmilo et 
al., 2000; Adamopoulos et al., 2002), results in increases in GH production, and it is well 
known that GH per se can induce lipolysis (Fain & Bahouth, 2000; Nam & Marcus, 2000; 
Sesmilo et al., 2000).  In recent studies, we have incubated 3T3 L1 adipocytes with IL-6 in the 
presence or absence of lipolytic hormones, including GH, and measured glycerol release as a 
marker of lipolysis.  Rather than augment the IL-6-induced lipolysis, GH tended to attenuate 
this response (Petersen et al., 2005a).  Therefore, although we cannot rule out the possibility 
that IL-6 is not directly associated with lipolytic processes, these preliminary studies would 
argue against such a hypothesis.  
 
Adrenaline has been suggested to be a hormone-mediating IL-6 production (Helge et al., 
2003) and actively increases IL-6 production when administered at supra-physiological and 
pharmacological concentrations (DeRijk et al., 1994; Vicennati et al., 2002; Frost et al., 
2004).  However, results pertaining from physiological situations are more applicable in 
deciphering the results of the present study.  A number of physiological studies suggest that 
adrenaline is unlikely to mediate the increased IL-6 mRNA and protein release.  An 
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adrenaline infusion in resting humans, which closely mimicked the exercise-induced increase 
in plasma adrenaline, increased plasma IL-6 only 4-fold, in contrast to the 30-fold increase 
observed during exercise (Starkie et al., 2001b).  In agreement, the previous study (Chapter 3) 
showed that physiological to pharmacological doses (10–1,000 nM) of adrenaline did not 
stimulated either IL-6 mRNA expression in, or protein release from, isolated rodent skeletal 
muscle.  As such, it is possible that the small elevation in plasma adrenaline induced by NA 
may have partly influenced the plasma levels of IL-6 during exercise.  It is unlikely that the 
small elevation in cortisol is responsible for the increase in plasma IL-6 seen with NA because 
cortisol has been demonstrated to down regulate plasma IL-6 in humans (Kunz-Ebrecht et al., 
2003).  Therefore, the observed changes in IL-6 are unlikely to be due to the changes observed 
in the hormonal milieu.  
 
The direct effect of NA on IL-6 production in the present study is not known.  NA has, 
however, been shown to decrease IL-6 by 95 % in whole blood in response to endotoxin 
(Ungerstedt et al., 2003).  The increase in adrenaline in resting and exercising humans due to 
NA is 30–40 % (Hawley et al., 2000) and is thus not likely to play a large part in the 
increases observed in the present study.  The vasodilatory effect of NA on peripheral blood 
vessels could potentially dilute circulating IL-6 levels rather than increase them, as IL-6 is not 
known to be induced by vasodilation, rather it itself induces vasodilation (Minghini et al., 
1998).  Hence, it is unlikely that NA had a pronounced effect on the present measurements 
other than FFA.  
 
Both IL-6 mRNA expression in (Steensberg et al., 2001a; Keller et al., 2003a), and protein 
release from (Steensberg et al., 2001a), skeletal muscle are augmented by reduced glycogen 
availability.  In the present study, CHO oxidation was augmented in NA compared with Con 
(Table 4.1), consistent with previous findings whereby NA administration increased the rate 
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of muscle glycogen utilization and whole body CHO oxidation during prolonged exercise 
(Carlson et al., 1963; Bergstrom et al., 1969; Gollnick & Hermansen, 1973).  Despite this, no 
statistical differences were observed in intramuscular glycogen levels when comparing trials 
(Figure 4.4), and despite the tendency for a difference at 180 min, the glycogen levels at 90 
min of exercise were almost identical, whereas the plasma IL-6 levels were much greater in 
NA at this time point, suggesting that glucose uptake and oxidation were elevated during the 
NA trial.  We have reported that muscle glycogen depletion increases IL-6 levels (Steensberg 
et al., 2001a); however, it appears that our present results were not solely mediated by 
glycogen availability.  Our laboratory's previous findings that an increase in glucose uptake 
and oxidation attenuate the increase in IL-6 release during exercise (Febbraio et al., 2003b) 
may appear contradictory to the present results; however, glucose uptake and oxidation were 
increased due to CHO ingestion such that the energy demand of exercise was met.  In the 
present study, however, energy demand was high, supporting the hypothesis that IL-6 increase 
is associated with increased metabolic demand.  To ascertain whether the increase in IL-6 is 
due to the lowering of plasma FFA per se or can be attributed to NA ingestion, further 
investigation is required whereby NA is administered in the presence of a maintained plasma 
FFA concentration such as obtained through an intralipid infusion.  
 
In conclusion, this study demonstrates that circulating IL-6 is markedly elevated at rest and 
during prolonged moderate-intensity exercise when lipolysis is suppressed.  Significant 
elevation of IL-6 gene expression in adipose tissue during exercise and further with plasma 
FFA suppression suggests that IL-6 may be released from active tissue beds such as adipose 
tissue and/or skeletal muscle during exercise and under metabolic challenge to mobilize fat in 
an "endocrine-like" manner, and such a hypothesis warrants further investigation.  
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CHAPTER FIVE 
 
 
 
ROLE OF INTERLEUKIN-6 DEFICIENCY ON DIET INDUCED 
INSULIN RESISTANCE IN MICE 
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5.1 Introduction 
 
The IL-6 knockout (IL-6-/-) mouse was generated more than 10 years ago by Kopf and 
colleagues (Kopf et al., 1994) as a way in which to circumvent a number of potential 
problems associated with the use of anti-IL-6 antibodies and provide a unique opportunity to 
study the function of IL-6 in the authentic absence of endogenous IL-6.   IL-6-/- mice have 
been shown to have normal development of organ systems and normal expression of 
functional cell surface markers on immune cell types (Kopf et al., 1994) and have been used 
as an experimental model on numerous occasions with regards to immunological parameters.  
However, only a few recent studies have investigated this mouse in the context of 
metabolism.  Of note, the over-expression of IL-6 results in growth retardation (De Benedetti 
et al., 2001; Lieskovska et al., 2002, 2003) and fatal renal failure in early life (Katsume et al., 
1997; De Benedetti et al., 2002; Katsume et al., 2002). 
 
Wallenius and colleagues reported that IL-6-/- mice spontaneously develop mature-onset 
obesity (Wallenius et al., 2002b).  These mice had significantly increased body fat compared 
with controls, elevated basal glucose levels, impaired glucose tolerance and elevated leptin.  
Interestingly, subsequent IL-6 treatment for 18-days significantly decreased body weight and 
leptin levels in the IL-6-/- mice, with no effect on control mice.  However, no mechanistic 
investigation was pursued in an attempt to explain this phenotype.  In direct contrast, Di 
Gregorio and colleagues (Di Gregorio et al., 2004) did not observe any differences in body 
mass, total body fat, glucose tolerance or insulin sensitivity between wild type and IL-6-/- 
mice at the same age as investigated by Wallenius (Wallenius et al., 2002b).  In addition, 
leptin levels were similar in IL-6-/-and WT, in contrast to previously reported three-fold 
elevations in IL-6-/- mice (Wallenius et al., 2002b).  Therefore, Di Gregorio and colleagues 
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concluded that IL-6-/- mice do not develop a phenotype indicative of mature-onset obesity or 
diabetes, but neither did they observe improved insulin sensitivity (Di Gregorio et al., 2004).  
 
The stark discrepancies between these two investigations at the phenotypic level are yet to be 
reconciled.  As evidenced by the literature, and discussed in the introduction, the controversial 
role, or perhaps multi-faceted roles of IL-6 in insulin resistance and glucose and fatty acid 
metabolism remain unclear.  Thus, the aim of this study was to further investigate the IL-6-/- 
mouse, in particular, to characterise the molecular regulation of insulin signalling and fat 
metabolism.  The hypothesis was that IL-6 deficiency would cause perturbed regulation of 
both fat metabolism and insulin signalling.   
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5.2 Methods 
 
Animals.  Eight-week old male C57BL/6 mice (wild type: WT) were purchased from Monash 
Medical Centre (Clayton, Victoria, Australia).  Eight-week old male IL-6 knockout mice were 
purchased from MouseWorks (Clayton, Victoria, Australia).  WT mice were used as a control 
as we were informed by the supplier of the IL-6 knockout mice that they were on a pure 
C57BL/6 background backcrossed at least 8 generations. Mice were housed under controlled 
temperature (21 °C) and lighting (12 hours of light, 0700–1900 hours; 12 hours of dark, 1900–
0700 hours) with free access to water and standard mouse chow until 10 weeks of age.  All 
experimental procedures were approved by the Animal Experimentation Ethics Committee of 
RMIT University (AEEC # 0419).  When mice were 10 weeks of age, the experimental 
protocol commenced (week 0).   Mice were put onto either a standard mouse chow (3 % fat, 
77 % carbohydrate, 20 % protein) or a high-fat diet (35.5 % fat, 35.7 % carbohydrate, 20 % 
protein; Diet F4837; Bio-Serv, Frenchtown, NJ; % by weight), both of which were available 
ad libitum, for 16 weeks.  This model of dietary-induced insulin resistance achieved by the 
high fat diet creates both fasting hyperglycemia and hyperinsulinemia, a reasonable model for 
the human insulin resistance (Surwit et al., 1988; Burcelin et al., 2002).  Daily food 
consumption was monitored for a 4-week period (weeks 6–10) and body mass was recorded 
weekly.  Daily caloric intake was calculated by multiplying the consumption of the diet by its 
caloric density provided by the manufacturer (chow: 4.15; HF: 5.43 kcal/g). 
 
IL-6 knockout verification.  To ensure that our mice were, in fact IL-6 knockout, WT and IL-
6-/- mice were stimulated intraperitoneally with a sublethal dose of lipopolysaccharide (LPS; 
1.0 µg/g bw), a potent inducer of IL-6 production (Kondo et al., 2001; Frost et al., 2003).  
After two hours, mice were anaesthetised with sodium pentobarbital (60 mg/kg; Sigma, St. 
Louis, Missouri, USA) and tissues (heart, spleen, liver, muscle, and plasma) were collected 
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for determination of IL-6 gene expression and protein by RT-PCR and western blot, 
respectively.  Tissues were extracted for total RNA and IL-6 gene expression was quantified 
and analysed as previously described (Chapter 3).  Western blot analysis for IL-6 protein was 
performed as described below.   
 
Glucose and insulin tolerance tests.  Glucose and insulin tolerance tests were performed on 
both strains of mice at week 8 and glucose tolerance tests were performed again at week 14.  
For glucose and insulin tolerance tests, mice were fasted for 6 h (0600–1200).  Fasting 
protocols for glucose and insulin tolerance tests and hyperinsulinemic-euglycemic clamps 
were the same for consistency and comparative reasons.  Six-hour fasting was chosen rather 
than overnight fasting for several reasons; i) mice are nocturnal feeders and overnight fasting 
would thus commence when they are in a low-consumption mode; ii) overnight fasting 
significantly decreases fat and muscle tissue and thus body weight (approximately 16%), 
decreases hepatic glycogen content, plasma glucose and insulin; iii) overnight fasting 
increases insulin sensitivity and makes maintenance of euglycaemia more difficult (Feuger et 
al. 2004; Ayala et al. 2006).   
 
An initial blood sample (t = 0) was taken from the tail for measurement of fasting glucose.  
For glucose tolerance tests dextrose (1 mg/g body mass) was administered intraperitoneally.  
Blood samples for glucose analysis were collected from the tail at 10, 20, 30, 45, 60, 90, and 
120 min following injection.  Blood glucose was measured from whole blood immediately 
using a HemoCue Glucose 201+ Analyser (HemoCue, Ängelholm, Sweden).  Blood for 
insulin measurement was taken at 0, 15, or 60 min (one measure per mouse) and treated with 
EDTA.  For insulin tolerance tests, insulin (recombinant human insulin; Actrapid; 0.85 
IU/kg body weight) was administered intraperitoneally and blood samples for glucose 
analysis were taken at 15, 30, 45, 60, 90, and 120 min after injection.  
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Surgical Procedures.  Approximately 2 weeks after the week-14 tolerance test, each mouse 
was implanted with 2 catheters (Micro-Renathane MRE 025, 0.025-inch outer diameter, 
0.012-inch inner diameter; Braintree Scientific Inc., Braintree, Massachusetts, USA) into the 
right jugular vein.  The anaesthetic cocktail consisted of ketamine hydrochloride (80 mg/kg; 
Fort Dodge Animal Health, Fort Dodge, Iowa, USA), acepromazine maleate (0.5 mg/kg; 
Butler Co., Columbus, Ohio, USA), and xylazine (1.6 mg/kg; Butler Co.) given 
intraperitoneally.  Catheters were tunnelled subcutaneously, exteriorized at the back of the 
neck, and filled with heparinized saline and sealed with stainless steel plugs.  Animals were 
each given approximately 1 mL of saline subcutaneously and were maintained on a heating 
pad for a 24-hour recovery period. 
 
Hyperinsulinemic-Euglycemic Clamp.  After 16 weeks on the high fat diet (approximately 6 
months of age) and four days after surgery, glucose turnover was measured in either the basal 
state or during a hyperinsulinemic-euglycemic clamp (the latter is a measure of insulin 
sensitivity).  Mice were fasted for 6 hours and then placed in a restrainer to which they had 
been conditioned on a daily basis for the previous 2 weeks.  Exteriorised catheters were 
exposed and plugs removed.  Micro-Renathane tubing was connected to the catheter lead, 
gently flushed with heparinized saline to confirm patency, and linked up to infusion syringes.  
Following basal blood glucose sampling the hyperinsulinemic-euglycemic clamp was 
performed by infusing recombinant human insulin (Novolin R; Novo Nordisk Pharmaceutical 
Industries Inc., Clayton, North Carolina, USA) at 6 mU/kg/min into the jugular cannula.  The 
insulin infusate comprised the relevant insulin volume, 100 µL/mL, 8% bovine serum 
albumin (BSA; Sigma, St. Louis, Missouri, USA) and was diluted to a final volume with 
saline (0.9 % NaCl).  Blood samples (5 µL) were drawn at 10 min intervals for the immediate 
determination of blood glucose using a HemoCue Glucose 201+ Analyser.  Based on these 
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values, 50% dextrose (Abbott Laboratories, Chicago, Illinois, USA) was variably infused into 
the other jugular catheter to maintain the plasma glucose concentration at approximately 7.8 ± 
0.2 mmol.  Steady state (stable plasma glucose concentration and exogenous glucose infusion 
rate for a minimum of 30 min) was generally achieved within 90–120 min.  Each animal was 
then promptly anaesthetised (ketamine hydrochloride; 80 mg/kg, acepromazine maleate; 0.5 
mg/kg, and xylazine; 1.6 mg/kg).  Soleus muscles from basal clamp animals were carefully 
excised tendon to tendon for fatty acid oxidation (see below).  Blood was collected from the 
inferior vena cava for insulin analysis.  Tissues (liver, skeletal muscle, brown and white 
adipose, heart, and spleen) were harvested and rapidly frozen in liquid nitrogen and stored at –
80 oC for subsequent analysis.  
 
Plasma Analysis.  Plasma insulin was measured by ELISA (#EZRMI-13K, Linco Research, 
Missouri, USA).  Free fatty acid content (FFA) was measured spectrophotometrically by an 
enzymatic colorimetric assay (Wako NEFA C kit; Wako Chemicals, Richmond, VA).   
 
Analysis of muscle and liver lipid species.  Intramuscular triacylglycerol (IMTG) content was 
analysed as previously described (Frayn & Maycock, 1980b).  Lipid was extracted from liver 
and muscle tissue by Folch extraction (Folch et al., 1957).  Wet tissue was homogenised in 
2.5 ml chloroform:methanol (2:1) plus 0.5 ml chloroform, then gently mixed with 1.5 ml 4 
mM MgCl2 and centrifuged at 100 g for 30 min.  The upper aqueous phase was carefully 
aspirated then 1.8 ml of the lower organic phase was transferred to another vial and 
evaporated under nitrogen at 37 oC.  Triacylglycerol was saponified to glycerol and FFA in 
250 µl warm ethanoic KOH (5 parts 80 % KOH : 95 parts absolute ethanol), incubated at 60 
oC for 60 min.  0.5 ml of 0.15 M MgSO4 was added and mixed thoroughly to neutralise the 
solution, which was then centrifuged at 10 000g for 2 min to pack down the precipitate.  The 
supernatant was collected and stored at –80 oC for fluorometric analysis of glycerol. The 
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extract was then analyzed for glycerol, with the absorbance at 340 nm determined before and 
after addition of glycerol kinase and glycerol-3-phosphate dehydrogenase.  Glycerol content 
was expressed as nanomoles per milligram of tissue (wet weight).  Diacylglycerol (DAG) and 
ceramide were extracted and quantified according to the methods described by Preiss and 
colleagues (Preiss et al., 1987).  Briefly, lipids were extracted from liver and mixed 
gastrocnemius muscle by homogenising tissue in 1.9 mL chloroform/methanol/PBS and 0.2 
% sodium dodecyl sulfate (1:2:0.8), adding 500 µl chloroform and thoroughly mixing.  The 
organic and solvent phases were separated by adding 500 µl 1 % perchloric acid, mixed and 
centrifuged at 2000 rpm for 2 min.  Without disturbing the tissue/chloroform interface, the 
upper layer was aspirated off, and then 450 µl of the lower chloroform phase was collected 
and dried under nitrogen in a 37 oC water bath.  The samples were then reconstituted in 400 µl 
chloroform/methanol (2:1) and mixed.  Samples were again dried under nitrogen (37oC).  The 
reaction was primed by adding 20 µl octyglucoside/cardiolipin to samples, mixed thoroughly, 
and allowed to stand for 10-15 min (RT).   A reaction mixture containing diacylglycerol 
kinase and [ -32P]ATP (15 µCi/µmol cold ATP) was added to extracts, gently mixed and 
incubated for 2-h (RT).  The reaction was stopped using 2 ml chloroform/methanol (2:1) and 
mixed thoroughly.  The phase was broken by addition of 500 µl 1 % perchloric acid and 
thoroughly mixing.  After centrifugation (5 min, 1000 rpm) the upper phase was aspirated off 
and a total of 830 µl of the lower phase recovered and dried under nitrogen (37oC).  Samples 
were mixed with 30 µl chloroform/methanol (2:1) and spotted onto thin layer chromatography 
plates, developed in chloroform/acetone/methanol/acetic acid/water (100:40:20:20:10) to two 
thirds of the total plate length.  Bands corresponding to DAG and ceramide were identified 
against standards after phosphoimaging, dried, scraped from the thin layer chromatography 
plate, and counted in a liquid scintillation analyser (Tri-Carb 2500TR, Packard, Canberra, 
Australia).  
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Fatty acid oxidation in soleus muscle:  
Pre-incubation and Pre-experimental labelling of the intramuscular lipid pools.  Soleus 
muscles were incubated in 2 ml of base buffer for 30 min to permit equilibration.  Briefly, 
muscle strips were removed from the pre-incubation buffer and transferred to a second vial 
with incubation medium containing 0.5 µCi/ml of [1-14C] palmitate (Amersham Life Science) 
for 90 min.  Palmitate oxidation and esterification were monitored by the production of 14CO2 
and incorporation of [1-14C] palmitate into endogenous lipids.   
 
Extraction of Muscle Lipids.  Muscles were placed in 13 ml plastic centrifuge tubes 
containing 5.0 ml of ice-cold 1:1 chloroform methanol (vol/vol) and homogenised using a 
polytron (Brinkman Instruments, Mississauga, ON, Canada).  Following homogenisation, 
samples were centrifuged at 2000 g (4°C) for 10 min.  The supernatant was removed with a 
glass Pasteur pipette and transferred to a clean centrifuge tube.  Distilled water (2.0 ml) was 
added, samples were shaken for 10 min, and centrifuged as before to separate the aqueous and 
lipophilic phases.  One ml of the aqueous phase was quantified by liquid scintillation counting 
to determine the amount of 14C labelled oxidative intermediates resulting from isotopic 
fixation.  This represented a 2-fold correction factor for exogenous 14C-palmitate oxidation.  
Gaseous 14CO2 produced from the exogenous oxidation of [1-14C] palmitate during the 
incubation was measured by transferring 1.0 ml of the incubation medium to a 20 ml glass 
scintillation vial containing 1.0 ml of 1 M H2SO4 and a 0.5 ml Fisher microcentrifuge tube 
containing 1 M benzethonium hydroxide. Liberated 14CO2 was trapped in the benzethonium 
hydroxide over 60 min, and the microcentrifuge tube containing trapped 14CO2 was placed in 
a scintillation vial and counted.  Total palmitate oxidation was calculated as oxidative 
intermediates plus 14CO2 produced. 
 
 68
Western blot analysis of tissue proteins.  Tissues were homogenized (Polytron; Brinkman 
Instruments, New York, NY, USA) in ice-cold buffer containing 50 mM HEPES, 150 mM 
NaCl, 10 mM NaF, 1 mM Na3VO4, 5 mM EDTA, 0.5 % Triton X-100, 10 % glycerol (v/v), 3 
µl/ml protease inhibitor cocktail, 100 µg/ml phenylmethylsulfonyl fluoride and 3 µl/ml 
phosphates inhibitor cocktail.  Homogenates were centrifuged and the supernatant was 
removed.  An aliquot was used to determine protein concentration (Pierce, Rockford, IL, 
USA). Subsequent aliquots of 100 ug protein were solubilized in 4 х Laemmli sample buffer 
and boiled for 5 min then rapidly frozen in liquid nitrogen and stored at –80 oC.  Tissue 
lysates were resolved by SDS-PAGE on 6-16 % polyacrylamide gels (120 V for 30 min, then 
140 V for approx 60 min), transferred to a nitrocellulose membrane (120 min; 0.06 
A/membrane), washed twice in TBST, blocked with 5% bovine serum albumin in TBS (120 
min at room temperature), washed thrice in TBST, and then immunoblotted with the relevant 
antibody (overnight at 4oC).   Antibodies used are as follows: anti-IRS-1, anti-IRS-2, anti-
phospho p85-IRS-1-PI3K, anti-phospho(Ser79)-ACC (Upstate Cell Signalling Solutions, Lake 
Placid, NY), anti-phospho (Tyr895)-IRS-1 (Oncogene Research Products, Boston, MA), anti-
phospho (Ser473)-Akt, anti-Akt, anti-phospho-AMPK-Thr172, anti-AMPK, anti-phospho-p38 
MAP kinase (MAPK) (Cell Signalling Technology, Beverly, MA), anti-UCP3 (Alpha 
Diagnostics, San Antonio, TX), anti-SOCS3, anti-TNFα, anti-phospho (Ser32)-IκBα, anti-IκBα 
(Santa Cruz Biotechnology, CA), anti-phosphoPGC1α or anti-PGC1α antibody (Chemicon 
International, Boronia, Victoria, Australia).  The next morning membranes were washed 
thoroughly in TBST (6 x 5 min) then incubated with horseradish peroxidase-conjugated 
secondary antibody (1:2000–1:4000; Amersham Biosciences, Castle Hill, NSW, Australia), 
then washed thoroughly again (3 x 5 min, 3 x 10 min).  The immunoreactive proteins were 
then detected with enhanced chemiluminescence (Amersham Biosciences, Buckinghamshire, 
England) on a Chemidoc XRS imaging system (BIO-RAD, Hercules, USA).  Proteins were 
quantified by densitometry (Quantity One 1-D Analysis Software).  Membranes were then 
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stripped (stripping buffer details; 5 min RT) of primary and secondary antibodies, washed, re-
blocked, and then probed with the corresponding total primary antibody.   All values reported 
are expressed relative to basal WT chow. 
 
AMPK α1 and α2 activity.  Lysates from muscle, liver and WAT were incubated with AMPK 
α1 and AMPK α2 antibody-bound protein A agarose beads for 2-h, immuno-complexes were 
washed and AMPK activity was determined in the presence of 200 µM AMP (Chen et al., 
2000). 
 
Statistical analysis.   Data was analyzed using a one way or two-way analysis of variance 
(ANOVA) with repeated measures (SPSS), with significance accepted with a P value of < 
0.05.  If analyses revealed a significant interaction, a Newman Keuls post-hoc test was used to 
locate specific differences.  Data are presented as means ± SEM. 
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5.3 Results 
 
IL-6 knockout verification.  Western blot analysis of IL-6 in spleen and muscle confirmed the 
deficit of IL-6 protein in IL-6-/- mice (Fig 5.1).  Results from RT-PCR also confirmed the 
absence of IL-6 in IL-6-/- mice as gene amplification was detected in WT and not IL-6-/- mice. 
On obtaining results that appeared contrary to the published literature (Wallenius et al. 2002) 
we decided to confirm that our WT mice were indeed the appropriate controls, by genetically 
testing the strains. Despite being told by the supplier of the IL-6 knockout litter that the mice 
were on a pure C57BL/6 background, genetic tests showed that the IL-6 knockout mice were 
on a mixed (C57BL/6 x 129J) background. This makes the comparison of our knockout mice 
with our WT mice difficult to interpret.  
  
Body and Tissue Mass.  Body mass of mice commencing the experimental protocol was not 
different between the strains (Table 5.1).  All mice increased body mass over the experimental 
timeframe in accordance with the expected growth rate.  During the 16-weeks of HF diet WT, 
but not IL-6-/- mice increased body mass compared with chow-fed mice (P < 0.05).  At the 
end of the experiment IL-6-/- mice on both diets had a lower body mass than WT mice (P < 
0.05; Table 5.1).  Various tissue masses of the groups are reported in Table 5.1.  Of note, 
muscle mass was not significantly different between strains.  White adipose depots were 
smaller in IL-6-/- mice (P < 0.05) and elevated by HF in both strains (P < 0.05).  The spleen 
and kidneys of IL-6-/- mice were heavier than those of WT mice (P < 0.05). 
 
Food intake.  As demonstrated in Table 5.1, WT mice on HF diet maintained the same daily 
energy intake as WT Chow mice.  IL-6-/- Chow mice had a greater daily energy intake then 
any other group of mice (P < 0.05), and IL-6-/- HF mice had a lower caloric intake than other 
groups (P < 0.05), which was accounted for by their lower body mass. 
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Glucose and insulin tolerance tests.  At week-8 fasting basal glucose was elevated in HF, 
consistent with induction of insulin resistance (P < 0.05).  In IL-6-/- fasting basal glucose 
levels were lower than that of WT on respective diets (P < 0.05; Table 5. 2).  After 14 weeks 
of the dietary protocol the fasting basal glucose concentrations in all groups had increased 
slightly, consistent with the aging of the animal, but the pattern of lower levels in IL-6-/- and 
elevated levels with HF was maintained (P < 0.05). 
 
Insulin tolerance tests performed at week-8 showed that IL-6-/- were much more sensitive to 
the insulin stimulus than WT (Figure 5.2).  Relative to WT chow the insulin bolus caused a 
greater drop in IL-6-/- chow blood glucose levels.  This observation also held true when values 
were expressed as a proportion of initial glucose levels, as IL-6-/- chow had lower basal 
glucose levels than WT (P < 0.05).  The recovery of glucose levels was not rapid in IL-6-/- 
chow because glucose levels were reduced to such low levels.  The insulin dose used was 
chosen because it is commonly used in the literature and preliminary studies showed that this 
dose elicited an approximately 50 % reduction in blood glucose in WT.  However, given the 
low glucose levels of IL-6-/-, a lower insulin dose should have been used, in which case we 
might have seen a restoration of glucose levels.  The insulin tolerance test did show that in 
WT the HF elicited an impaired ability to restore blood glucose.  Expressing glucose values as 
a percentage of basal glucose, the area under the curve for WT chow was 64 ± 5 % where as 
that for WT HF was 55 ± 3 %, that of IL-6-/- HF was 47 ± 3 %, but how this relates to IL-6-/- 
chow cannot be established through this line of data.  It was deemed unnecessary to perform 
ITT at week-14, as the hyperinsulinemic-euglycemic clamp at week-16 was a more rigorous 
measure of insulin sensitivity. 
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The glucose bolus administered for the glucose tolerance test increased WT and IL-6-/- chow 
and HF glucose levels to a similar extent above baseline (175 ± 9 %; 171 ± 6 % respectively, 
P < 0.05).  Figure 5.3 shows the glucose concentrations during GTT at week-8.  This test 
shows that IL-6-/- chow are more glucose tolerant than WT chow.  After 8 weeks the HF diet 
had impaired glucose tolerance in WT and even more so in IL-6-/- as indicated by the elevated 
curve (P < 0.05).  The characteristic of lower glucose in IL-6-/- and the effect of HF persisted 
at week-14 (P < 0.05; Figure 5.3).  Interestingly, by week-14 IL-6-/- HF had rectified their 
glucose tolerance to a large extent and their presiding impairment at this time was similar to 
that seen in WT.  When these glucose curves are expressed as the area under the curve 
(AUC), i.e. the amount of glucose in circulation during the 120 min, the status of glucose 
tolerance becomes more apparent.  AUC for WT HF was higher than WT chow (P < 0.05).  
This was also the case in IL-6-/- (P < 0.05).  The lower basal glucose in IL-6-/- could account 
for the AUC for IL-6-/- being lower than WT.  In fact, when AUC was calculated relative to 
baseline glucose levels, AUC for IL-6-/- chow and HF tended to be lower than WT, although 
did not reach significance (169±6; 170±7; 181±5; 192±6% respectively). 
 
Hyperinsulinemic-euglycemic clamp.  The week-14 fasting glucose measures of all animals 
were averaged and the resulting value, 7.8 ± 0.2 mmol, was deemed to be the glucose 
concentration which all mice would be clamped at when maintaining euglycemia.  There were 
no differences between groups regarding the level of euglycemia; all animals were clamped at 
7.7 ± 0.2 mmol (Figure 5.4).  The glucose infusion rate for WT chow was 62.5 ± 8.2 
mg/kg/min.  This value means that for the 6 mU/kg of insulin being infused, approximately 
62.5 mg/kg of glucose was required to maintain the blood glucose at approximately 7.7 mmol.  
This value was lower in WT HF (47.4 ± 9.6 mg/kg/min: P < 0.05) meaning that there was a 
lesser degree of insulin-stimulated glucose disposal and thus WT HF were less insulin 
sensitive than WT chow.   IL-6-/- chow were more insulin sensitive than WT chow, with a 
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GIR of 93.4 ± 9.4 mg/kg/min (P < 0.05).  Insulin sensitivity of IL-6-/- was impaired by HF 
(GIR 62.4 ± 3.4 mg/kg/min), however this was comparable to WT chow GIR (Figure 5.4).   
 
Plasma measures.  FFA were lower in HF groups of both strains and lower in IL-6-/- than WT 
when compared with WT chow (P < 0.05; Table 5.2).  This was an unexpected finding, but 
likely due to metabolic flexibility allowing a shift to greater fat metabolism when confronted 
with high fat consumption.  Basally, plasma insulin was lower in IL-6-/- chow than WT chow 
(P < 0.05).  HF increased insulin in WT and IL-6-/-.  When insulin measures from ITT were 
calculated as AUC, there were no differences between the strains, but higher values in HF 
groups (P < 0.05; Table 5.2). 
 
Homeostasis model assessment of insulin resistance (HOMA-IR):  Insulin resistance was 
estimated by HOMA-IR and was defined as fasting plasma insulin (µU/ml) x fasting plasma 
glucose (mmol/l)/22.5 (Matthews et al., 1985).  The HOMA method has been shown to be a 
useful measure for assessing insulin resistance across a wide range of glucose levels in the 
human population (McAuley et al., 2001).  HOMA-IR indicated that HF impaired insulin 
sensitivity in both strains (P < 0.05; Table 5.2). 
 
Triacylglycerol content of gastrocnemius muscle and liver.  Levels of TAG in gastrocnemius 
muscle were lower in IL-6-/- chow than WT chow (P < 0.05).  HF increased TAG content in 
both strains (P < 0.05), with similar levels observed in WT and IL-6-/- HF (Figure 5.5).  
Levels of TAG in liver tissue were lower in IL-6-/- than WT (P < 0.05).  HF increased TAG 
content in both strains (P < 0.05), but levels in IL-6-/- HF were much lower than WT HF (P < 
0.05) and were similar to WT chow (Figure 5.5).  
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Diacylglycerol and ceramide content of gastrocnemius muscle and liver.  Gastrocnemius 
muscle DAG content was not different between WT and IL-6-/- chow, but was elevated by HF 
(P < 0.05), although to a lower extent in WT HF than IL-6-/- HF tissue (P < 0.05; Figure 5.5).  
Liver DAG content was lower in IL-6-/- chow than WT chow (P < 0.05), and was neither 
affected by HF nor different between strains on HF.  Gastrocnemius muscle ceramide content 
was elevated in IL-6-/- chow (P < 0.05), but not significantly altered by HF in either strain 
(Figure 5.5).  Liver ceramide content was elevated in IL-6-/- compared with WT on both diets 
(P < 0.05).   
 
Soleus fatty acid oxidation.  Oxidation of palmitate in soleus muscles under basal conditions 
was higher in IL-6-/- than WT in both diet groups (P < 0.05) and HF decreased palmitate 
oxidation in both strains (P < 0.05; Figure 5.6).  
 
Insulin signalling proteins in liver and skeletal muscle.  Total IRS-1 and -2 protein in liver 
were increased in IL-6-/- chow (P < 0.05) but not other groups compared with WT chow.  No 
differences were seen in total IRS-1 or -2 protein in gastrocnemius muscle (Figure 5.7).  IRS-
1-associated PI3K regulatory subunit, p85, was not detectably different between groups but 
was increased with insulin stimulation (Figure 5.8).  No differences were seen in IRS-1 Tyr895 
phosphorylation (Figure 5.8). 
 
Akt in liver and skeletal muscle.  HF in WT did not affect total Akt in liver, and IL-6-/- HF was 
not different to WT.  However, total Akt was higher in IL-6-/- chow compared with WT chow 
and IL-6-/- HF (P < 0.05).   Basal Ser473 phosphorylation (pSer473) of Akt was lowered by HF 
in WT (P < 0.05) but not IL-6-/-, and was lower in IL-6-/- chow than WT (P < 0.05).  Insulin 
stimulation increased pSer473 in all groups to a similar level (P < 0.05; Figure 5.9). 
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Peroxisome proliferator activated receptor gamma coactivator 1 (PGC1α) in liver and 
skeletal muscle.  PGC1α, a regulator of transcription enzymes necessary for substrates 
oxidation was measured in muscle and liver tissue.  Gastrocnemius muscle PGC1α was not 
different between strains or diets, however there was a trend to increase levels in IL-6-/- HF (P 
= 0.09).  Liver PGC1α was decreased in both strains with HF compared with WT chow 
(Figure 5.10).  
 
AMP-activated protein kinase (AMPK) in liver, skeletal muscle and adipose tissue. AMPK is 
a known cellular energy sensor, the phosphorylation of which, at Thr172 (pAMPK), was 
investigated as a measure of its activation status.  Total AMPK protein was not different 
between the strains or diets in WAT, liver, gastrocnemius or quadriceps tissues.  Basal 
phosphorylation of AMPK at Thr172 was elevated in WAT (P < 0.05), decreased in liver (P < 
0.05), and not different in gastrocnemius muscle of IL-6-/- chow compared with WT chow.  
HF decreased AMPK Thr172 phosphorylation in liver of both strains (P < 0.05; Figure 5.11). 
 
AMPK α1 and α2 activity in liver, skeletal muscle and adipose tissue.  WAT AMPK α1 
activity was higher in IL-6-/- mice than WT mice (P < 0.05).  Liver AMPK α1 activity tended 
to be lower in IL-6-/- mice than WT mice (borderline significance P = 0.06).  No differences 
were seen between the strains in liver α2, quad α1 or α2 activity (Figure 5.12). 
 
Acetyl-CoA carboxylase (ACC) in liver, skeletal muscle and adipose tissue.  Phosphorylation, 
and thus inhibition, of ACC, to allow fatty acid oxidation, was increased in WAT (P < 0.05) 
and tended to be decreased in liver and quadriceps muscle of IL-6-/- mice compared with WT 
mice (borderline significance P = 0.08, P = 0.06, respectively; Figure 5.13).   
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Uncoupling protein 3 (UCP3) in adipose tissue.  WAT UCP3 was increased in IL-6-/- HF (P < 
0.05) but not WT HF compared with WT chow in the basal state (Figure 5.14).     
 
Suppressor of cytokine signalling 3 (SOCS3) in liver and skeletal muscle.  HF did not alter 
SOCS3 protein in liver tissue or gastrocnemius muscle. No differences were seen between the 
strains in liver tissue, but SOCS3 was ~10% lower in basal IL-6-/- gastrocnemius muscle 
compare with WT (P = 0.08; Figure 5.15).   
 
Tumour necrosis factor alpha (TNFα) in liver.  Basally, TNFα was elevated in liver of all 
groups compared with WT chow (P < 0.05) but was not different between the strains on HF 
(Figure 5.16).   
 
Inhibitor of kappa B alpha (IκBα) in liver.  Total IκBα protein in liver was not different 
between strains or diets.  pSer32 IκBα was increased basally in chow and HF IL-6-/- compared 
with WT chow and HF (P < 0.05; Figure 5.17). 
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Table 5.1  Food intake and tissue mass of WT and IL-6-/- mice on chow and HF diets.  
Tissue mass is reported in mg from 26-week old mice.  All data are expressed as mean ± 
SEM (n = 12-16). # P < 0.05 vs. WT; § P < 0.05 vs. Chow. 
Wild Type IL-6 -/-   
Chow HF Chow HF 
Age (weeks) 26 ± 0 26 ± 0 26 ± 0 26 ± 0 
Food intake (kcal/d) 18.2 ± 0.4 17.3 ± 0.8 19.9 ± 0.5# 14.0 ± 0.3# 
Body Mass 10wo (g) 27.6 ±0.4 - 27.8 ±0.4 - 
Body Mass 26wo (g) 33.7 ± 0.3 36.5 ± 0.9§ 32.1 ± 0.2# 32.0 ± 0.8# 
Heart  157.1 ± 7.4 143.5 ± 5.8§ 158.7 ± 6.0 150.9 ± 3.5 
Spleen  101.2 ± 5.3 100.5 ± 7.6 159.0 ± 12.6# 123.7 ± 7.0# 
Kidney  204.0 ± 3.4 - 242.5 ± 10.9# - 
Soleus  16.1 ± 0.8 - 12.1 ± 0.4# - 
EDL  9.3 ± 0.4 8.5 ± 0.6 8.8 ± 0.5 9.7 ± 0.5 
Tibialis Anterior  32.5 ± 1.3 32.1 ± 1.1 31.0 ± 1.0 31.1 ± 1.4 
Quadriceps Muscle  129.2 ± 4.1 124.8 ± 5.2 126.0 ± 5.1 129.4 ± 3.2 
BAT  62.0 ± 5.2 59.8 ± 4.9 69.5 ± 6.5 54.9 ± 3.1§ 
Infrarenal adipose pad  6.8 ± 0.9 18.9 ± 2.8§ 1.2 ± 0.2# 12.2 ± 2.2# § 
Epididymal adipose 
pad  
32.8 ± 4.9 39.8 ± 5.6§  5.3 ± 0.4# 24.6 ± 2.8# § 
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Table 5.2  Basal plasma measures from 6-h fasted mice.  All data are expressed as mean 
± SEM (n = 12-16). # P < 0.05 vs. WT; § P < 0.05 vs. Chow. 
Wild Type IL-6 -/- KO  
Chow HF Chow HF 
Glucose (mmol)     
Week 0 7.8 ± 0.4 - 5.7 ± 0.4# - 
Week 8 8.1 ± 0.4 9.7 ± 0.3§ 6.1 ± 0.3# 7.4 ± 0.4# § 
Week 14 9.1 ± 0.3 10.4 ± 0.3§ 6.9 ± 0.3# 7.8 ± 0.4# § 
FFA (mmol) 0.68 ± 0.09 0.39 ± 0.03§ 0.52 ± 0.04# 0.35 ± 0.04§ 
Insulin (ng/ml) 0.55 ± 0.07 0.95 ± 0.16§ 0.47 ± 0.07# 0.65 ± 0.08# § 
HOMA-IR 5.2 ± 0.7 6.9 ± 0.9 3.7 ± 0.5 4.2 ± 0.5 
AUC (GTT 
insulin) 
41.0 ± 3.5 60.5 ± 4.6§ 41.7 ± 2.7 56.1 ± 4.7§ 
 
 79
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1  IL-6 protein in LPS-stimulated spleen and muscle tissue of WT (solid bars) and 
IL-6-/- (open bars) mice.   Representative blots are shown.  All data are expressed relative WT 
as mean ± SEM (n = 6). # P < 0.05 vs. WT. 
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Figure 5.2  Glucose measures during insulin tolerance tests (0.85mU/g bm) performed at 
week-8 in WT chow (▬■▬) and HF (---■---), and IL-6-/- chow (▬◊▬) and HF (---◊---) 
mice.   Glucose data are expressed as area under the curve (AUC) for 120-min insulin 
tolerance test in WT (solid bars) and IL-6-/- (open bars) chow and HF mice. All data are 
expressed as mean ± SEM (n = 12). # P < 0.05 vs. WT; § P < 0.05 vs. chow. 
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Figure 5.3  Glucose measures during glucose tolerance tests (1 mg/g bm) performed at week-
8 (left) and week-14 (right) in WT chow (▬■▬) and HF (---■---), and IL-6-/- chow (▬◊▬) 
and HF (---◊---) mice.   Glucose data expressed as area under the curve (AUC) for 120-min 
glucose tolerance test in WT (solid bars) and IL-6-/- (open bars) chow and HF mice. All data 
are expressed as mean ± SEM (n = 12). # P < 0.05 vs. WT; § P < 0.05 vs. chow. 
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Figure 5.4  Plasma glucose of mice during steady state of the hyperinsulinemic-euglycemic 
clamp (upper).  Glucose infusion rate (GIR) at euglycemia with 6 mU/kg/min insulin infusion 
in WT (solid bars) and IL-6-/- (open bars) chow and HF mice.  All data are expressed as mean 
± SEM (n = 12). # P < 0.05 vs. WT; § P < 0.05 vs. chow. 
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Figure 5.5  Triacylglycerol (upper), diacylglycerol (middle), and ceramide (lower) content in 
skeletal muscle (left) and liver tissue (right) of WT (solid bars) and IL-6-/- (open bars) chow 
and HF mice.  All data are expressed as mean ± SEM (n = 12). # P < 0.05 vs. WT; § P < 0.05 
vs. chow. 
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Figure 5.6  Palmitate oxidation in soleus muscles of WT (solid bars) and IL-6-/- (open bars) 
chow and HF mice.  All data are expressed as mean ± SEM (n = 12). # P < 0.05 vs. WT; § P < 
0.05 vs. chow. 
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Figure 5.7  Basal gastrocnemius muscle (left) and liver tissue (right) IRS1 (upper) and IRS2 
(lower) protein of WT (solid bars) and IL-6-/- (open bars) chow and HF mice.  Representative 
blots are shown.  All data are expressed relative to WT chow as mean ± SEM (n = 6). # P < 
0.05 vs. WT; § P < 0.05 vs. chow. 
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Figure 5.8  Basal and insulin-stimulated liver tissue IRS1 Tyr 895 phosphorylation (upper) 
and IRS1-associated PI3K p85 protein (lower) of WT (solid bars) and IL-6-/- (open bars) chow 
and HF mice.  Representative blots are shown.  All data are expressed relative to WT chow as 
mean ± SEM (n = 6). # P < 0.05 vs. WT; § P < 0.05 vs. chow. 
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Figure 5.9  Akt Ser473 phosphorylation (upper), total protein (middle), and phosphorylation 
relative to total (lower) in liver tissue of WT (solid bars) and IL-6-/- (open bars) chow and HF 
mice under basal and insulin-stimulated conditions as indicated.  Representative blots are 
shown.  All data are expressed relative to basal WT chow as mean ± SEM (n = 6). # P < 0.05 
vs. WT; § P < 0.05 vs. chow.  
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Figure 5.10  PGC1α protein in gastrocnemius muscle (upper) and liver tissue (lower) of WT 
(solid bars) and IL-6-/- (open bars) chow and HF mice.  Representative blots are shown.  All 
data are expressed relative to WT chow as mean ± SEM (n = 6). # P < 0.05 vs. WT; § P < 0.05 
vs. chow.  
WT         IL-6-/- 
Chow   HF   Chow   HF 
WT         IL-6-/- 
Chow   HF   Chow   HF 
  
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
Chow HF
P
G
C
1α
 
Li
ve
r 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
1.4 
Chow HF
PG
C
1α
 
G
as
tro
§ §
 89
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 5.11  AMPK Thr172 phosphorylation relative to total AMPK protein in gastrocnemius 
muscle (upper), liver (middle), and white adipose tissue of WT (solid bars) and IL-6-/- (open 
bars) chow and HF mice.  Representative blots are shown.  All data are expressed relative to 
WT chow as mean ± SEM (n = 6). # P < 0.05 vs. WT; § P < 0.05 vs. chow.  
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Figure 5.12  AMPK α1 and α2 subunit activity in liver tissue (upper), quadriceps muscle 
(middle), and epididymal white adipose tissue (lower) of chow-fed WT (solid bars) and IL-6-/- 
(open bars) mice.  All data are expressed as mean ± SEM (n = 12). # P < 0.05 vs. WT. 
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Figure 5.13  ACCβ phosphorylation in quadriceps muscle, liver, and epididymal white 
adipose tissue (WAT) of chow-fed WT (solid bars) and IL-6-/- (open bars) mice.  
Representative blots are shown.  All data are expressed as a proportion of total protein relative 
to WT and reported as mean ± SEM (n = 6). # P < 0.05 vs. WT. 
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Figure 5.14  UCP3 in epididymal white adipose tissue of chow-fed WT (solid bars) and IL-6-
/- (open bars) mice.  Representative blots are shown.  All data are expressed relative to WT 
and reported as mean ± SEM (n = 6). # P < 0.05 vs. WT. 
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Figure 5.15  SOCS3 protein in liver tissue of WT (solid bars) and IL-6-/- (open bars) chow 
and HF mice.  Representative blots are shown.  All data are expressed relative to WT chow as 
mean ± SEM (n = 6). # P < 0.05 vs. WT; § P < 0.05 vs. chow.  
 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
Chow HF
Li
ve
r 
S
O
C
S
3 
Chow                  HF 
  WT       IL-6-/-     WT     IL-6-/-
 94
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16  TNFα protein in liver tissue of WT (solid bars) and IL-6-/- (open bars) chow and 
HF mice.  Representative blots are shown.  All data are expressed relative to WT chow as 
mean ± SEM (n = 6). # P < 0.05 vs. WT; § P < 0.05 vs. chow.  
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Figure 5.17  IκBα Ser32 phosphorylation relative to total IκBα protein in basal (left) and 
insulin stimulated (right) liver tissue of WT (solid bars) and IL-6-/- (open bars) chow and HF 
mice.  Representative blots are shown.  All data are expressed relative to WT chow as mean ± 
SEM (n = 6). # P < 0.05 vs. WT; § P < 0.05 vs. chow.  
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5.4 Discussion 
 
There is conflicting literature regarding the effect of IL-6 knockout on metabolism (Wallenius 
et al., 2002b; Di Gregorio et al., 2004).  In the present study, we did not detect the error in the 
genetic background of the animals, until we started the analyses.  Therefore, the fact that our 
mice were on different genetic backgrounds makes comparisons very difficult to interpret.  In 
general, however, data from this study demonstrate that IL-6-/- mice display low basal 
glucose, rapid glucose elimination, and a high rate of insulin-stimulated glucose utilisation 
compared with WT.  Thus, they are markedly glucose tolerant and insulin sensitive, which is 
likely to be the consequence of improved fat metabolism.  The investigation also confirms the 
development of glucose intolerance and insulin resistance in high fat-fed mice. 
 
Despite the fact that comparisons are difficult to make when comparing WT with IL-6-/- mice, 
when one carefully examines the data within rather than between groups, our data suggest two 
major findings.  The first is that the genetic background of the mice is very important when 
studying metabolic parameters.  The second is that, at least in mice that are on a mixed 
(C57BL/6 x 129J) background, IL-6 knockout prevents some of the deleterious effects of diet 
induced obesity.  Wallenius and colleagues (Wallenius et al., 2002b) reported that IL-6 
knockout resulted in greater weight gain as the mice aged.   In our study, this was not the 
case.  As can be seen in Table 5.1, there was no difference when comparing strains at 10 or 26 
weeks of age.  Moreover, at 26 weeks the IL-6-/- mice were resistant to weight gain on the HF 
diet.  This suggests that when the IL-6 knockout is made in a mouse on a mixed background, 
it is protected from the deleterious effects of a HF diet.  It is reasonable to expect that the 
sensitivity of determining food intake was similar for all groups, thus the lower body mass 
and energy intake of IL-6-/- HFmice may account for some of the observations but cannot be 
quantitatively assessed.  A mechanism for decreased food intake warrants investigation. 
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The HF diet was effective in reducing glucose tolerance and inducing insulin resistance.  This 
was reflected by increased basal blood glucose, increased AUC during GTT, and reduced GIR 
during the clamp in HF-fed animals.  Moreover, relative HF-induced impairments of many 
measured parameters were similar in each strain.  Of note, the GTT area under the curve 
(Figure 5.3), GIR during the clamp (Figure 5.4) and the rates of fatty acid oxidation in muscle 
(Figure 5.6) were all similarly affected when animals were placed on a HF diet.  This may 
suggest that the effect of genetic background was quantitatively more important than deletion 
of IL-6, as the mice responded similarly when subjected to the diet.   
 
 
Targeted mutagenesis in mice is a powerful tool for the analysis of gene function and human 
disease.  The recognition that different inbred strains harboured different susceptibilities for 
the development of obesity and diabetes came about as early as the 1970s.  It was observed 
that the spontaneous mutation of the leptin gene (ob/ob) or the leptin receptor gene (db/db) 
brought about disparate phenotypes depending whether it occurred in the C57BL/KsJ or 
C57BL/6 strain (Hummel et al., 1972; Coleman & Hummel, 1973).  It is becoming 
increasingly popular to manipulate candidate genes in mouse models in order to assess the 
impact of a particular genetic defect in the context of glucose metabolism and the 
development of type 2 diabetes (Valet et al., 2002; Kahn, 2003; Andrikopoulos et al., 2005).  
However, as more investigations have been reported, the clearer it has become, that the same 
genetic alteration, when present on different genetic backgrounds, results in profoundly 
different phenotypes. 
  
The IL-6-/- mice studied by Wallenius, Di Gregorio, Faldt, and Kelly and colleagues were 
reported as being backcrossed with C57BL/6, C57BL/6J-Il6, C57BL/6, and C57black mice 
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respectively (Wallenius et al., 2002b; Di Gregorio et al., 2004; Faldt et al., 2004; Kelly et al., 
2004).  The mice used in this study were thought to have a C57BL/6 genetic background.  
However, only after completion of the study, was it discovered that the IL-6-/- mice used were 
in fact derived from interbreeding C57BL x 129 F1 animals to obtain mice homozygous for 
the IL-6 allele, not from the C75BL/6 strain, as believed.  This fact makes one dubious of 
making any comparison between the results of the studies, specifically those utilizing 
different strains.  Primarily, the WT data cannot be considered appropriate controls with 
which to compare the IL-6-/- data.  Andrikopoulos and colleagues recently investigated the 
differential effect of C57BL/6 and 129 mouse strains on high fat diet on glucose-induced 
insulin release (Andrikopoulos et al., 2005).  This study helps us to resolve what of our 
findings may be the consequence of differences in background strain.  According to 
Andrikopoulos, compared with C57BL/6, 129 mice have greater body mass and epididymal 
fat pad mass on a chow diet; the same weight gain and fat mass on HF; higher basal plasma 
glucose; decreased insulin levels; are glucose intolerant; and secrete less insulin in response to 
glucose.  This phenotype is in contrast to, and thus does not appear to account for, the marked 
insulin sensitivity observed in IL-6-/- mice investigated here. However, this comment is 
speculative.  Further to this, Simpson and colleagues report that within the 129 strain 
substrains exist, and that deliberate and accidental outcrossing of substrains leads to extensive 
genetic variability (Simpson et al., 1997).  Purely acquiring a C57BL x 129 mouse line would 
not be considered an acceptable control.  Stringent breeding criteria and thorough inbreeding 
are mandatory in order to achieve appropriate littermates, homozygous for the IL-6 allele, to 
serve as true control animals.   This study highlights the fact that investigators need to be very 
cautious, firstly when selecting animal lineage on which to conduct research, and secondly 
when evaluating results, both self-generated and published by others.  It is very clear from this 
investigation that stark differential effects arise from the same genetic mutation, which is 
presumably primarily the result of a difference in background strain and may also be 
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attributed to differences in rearing and environment.  The state of IL-6 deficiency in mice has 
now been shown to cause profound insulin resistance and obesity (Wallenius et al., 2002b), 
no obvious phenotype (Di Gregorio et al., 2004), and profound insulin sensitivity and fat 
metabolism (current study).  Such results are likely to be just as varied within and between 
other species when studied under varying parameters. 
 
 
Taking into consideration possible variation due to genetic background it is difficult to make 
comparisons with investigations in alternative backcrosses.  However, upon considering the 
differential phenotypes of the C57BL/6 and 129 mice, it is difficult to believe that such is the 
root of the disparate phenotype of mice observed in this study.  The absence of a phenotype 
described by Di Gregorio and colleagues (Di Gregorio et al., 2004) compared with that by 
Wallenius and colleagues (Wallenius et al., 2002b) can plausibly be attributed to slight 
differences in genetic background.  However, that our results are in stark contrast to 
Wallenius and colleagues is of concern.  While the literature is at times contradictory with 
respect to the actions of IL-6 on insulin signalling and metabolic regulation, there is much 
support for our findings.  Of note, Klover and colleagues used antibodies against IL-6 to 
deplete IL-6 levels in obese insulin resistant mice and found that IL-6 depletion significantly 
improved insulin signalling (Klover et al., 2003).  Cai and colleagues also demonstrated 
improved insulin sensitivity in mice by systemic neutralization of IL-6 (Cai et al., 2005).   
Further, Kim and colleagues treated mice with IL-6 for 5-days and found this to drastically 
reduce skeletal muscle glucose uptake and insulin signalling (Kim et al., 2004a).  Thus we 
conclude that the IL-6 deficient (C57BL x 129) mice are markedly insulin sensitivity.  In 
conjunctin with the literature and the previous findings in this thesis we believe that this 
phenotype may be due to improved metabolism of lipid.  However, the limitations of this 
study mean that this phenotype can not be attributed to the IL-6 deletion alone as HF-induced 
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impairments were comparable between IL-6-/- and WT strains and decreased food intake in 
IL-6-/- HF warrants further investigation.  Further stringent investigations are required.  
Firstly, to fully characterise strain-specific metabolic regulation, and secondly, to tease apart 
the many confounding processes associated with IL-6 and its aetiology in insulin sensitivity 
and metabolism.  
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CHAPTER SIX 
 
 
 
INTERLEUKIN-6 TREATMENT IMPAIRS GLUCOSE TOLERANCE 
AND AMPK ACTIVATION IN IL-6-/- AND WT MICE 
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6.1 Introduction 
 
In the previous chapter an attempt was made to elucidate the role of IL-6 in metabolic 
processes using a “loss of function” approach, that being the study of mice with IL-6 deletion.  
As discussed, we discovered that our IL-6-/- mice were on a different genetic background 
compared with our WT mice, making it very difficult to determine whether the positive 
phenotype observed in our IL-6-/- mice was due to the deletion of IL-6 or due to the specific 
genetic background of the mice.  In order to answer this question, we next decided to adopt a 
“gain of function” approach, that being chronic treatment of the WT and IL-6-/- mice with 
recombinant mouse IL-6.  We rationalised that should the responses to rmIL-6 treatment be 
similar when comparing the WT and IL-6-/- mice, then the results seen in the previous chapter 
would be more likely due to the genetic deletion of IL-6. 
   
It is noteworthy that the majority of the studies reported in the literature that have treated mice 
with IL-6 have reported a negative phenotype with respect to insulin action.  IL-6 treatment in 
mice during an hyperinsulinemic-eyglycemic clamp results in insulin resistance  as evidenced 
by reduced GIR, whole body glucose turnover, skeletal muscle glucose uptake, IRS1-
associated PI3K (muscle), IRS2-associated PI3K (liver), glycolysis (whole body and skeletal 
muscle), and liver fatty acylCoA, and increased muscle fatty acylCoA and hepatic glucose 
production (Kim et al., 2004a).  In addition, two studies from Robert Mooney’s group in 
Rochester support the hypothesis that IL-6 leads to insulin resistance.  In their first study, 
chronic IL-6 treatment (5-day) lead to the development of insulin resistance in liver tissue and 
not skeletal muscle (Klover et al., 2003).  The chronic IL-6 exposure in vivo inhibited the 
ability of insulin to signal through its receptor and to phosphorylate two major metabolic 
substrates, IRS1 and IRS2.  In their second study, they reported that, in diet-induced obese 
(ob/ob) mice, depletion of IL-6 using neutralizing antibodies improved insulin responsiveness 
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in 2-h insulin tolerance tests (Klover et al., 2005).  From these studies, it appears that IL-6 
promotes insulin resistance and, in this context, our results presented in the previous chapter 
would tend to suggest that the results were attributable to IL-6 deletion and not genetic 
background. 
 
It must be noted, however, that not all studies demonstrate that IL-6 treatment leads to insulin 
resistance.  We have previously reported that acutely treating type 2 diabetic human patients 
with IL-6 normalises insulin sensitivity as measured by the HOMA-IR (Petersen et al., 
2005a).  Moreover, in unpublished work from our laboratory, humans infused acutely with 
physiological levels of IL-6 during an hyperinsulinemic-eyglycemic clamp displayed 
improved peripheral insulin sensitivity (Carey et al in review after revision).  Finally, as 
reported in a subsequent chapter of this thesis (Chapter 7), treating rats with IL-6 for 14 days 
markedly improved glucose tolerance. 
 
The aim of this study, therefore, was to determine whether the differences observed between 
WT and IL-6-/- mice in the previous study were the consequence of a direct effect of the 
absence of IL-6, or due to differences in the genetic background of the mice.  Accordingly, we 
repeated the study design of the previous chapter (placing WT and IL-6-/- mice on a HF diet), 
with or without rmIL-6 treatment for 14 days.  The hypothesis was that IL-6 treatment would 
alter the phenotype of IL-6-/- mice to be more like that of WT mice; i.e. impair glucose 
tolerance, insulin sensitivity and regulation of fat metabolism. 
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6.1 Methods 
 
Animals and IL-6 treatment.  The description of the mice was identical to that reported in the 
previous chapter (Chapter 5). 
 
After 8 weeks on the diet, which was sufficient to induce insulin resistance, fasting 
hyperglycemia and hyperinsulinemia, as demonstrated in Chapter 5, mice were treated with 
recombinant murine (rm) IL-6 or vehicle.  Alzet mini osmotic pumps (model no. 1002; 
Durect, Cupertino, CA), with a 101 ± 2 µl capacity and an infusion rate of 0.21 ± 0.01 µl/h 
were used.  Pumps were filled to capacity with 4 µg/ml rmIL-6 diluted in carrier (0.9% NaCl 
and 0.1% BSA) resulting in a daily delivery of approx 201 ng rmIL-6.  Pumps were prepared 
as per the directions supplied and incubated at 37oC overnight to ensure steady state pumping 
was achieved by the time of implantation.  Mice were anaesthetised with a cocktail consisting 
ketamine hydrochloride (80 mg/kg; Fort Dodge Animal Health, Fort Dodge, Iowa, USA), 
acepromazine maleate (0.5 mg/kg; Butler Co., Columbus, Ohio, USA), and xylazine (1.6 
mg/kg; Butler Co.) given intraperitoneally.  A small incision was made in the skin on the back 
of the neck and pumps were implanted in a dorsal orientation into the intrascapular 
subcutaneous space.  Incisions were closed with interrupted surgical silk sutures.  Control 
(saline-treated) animals received pumps containing vehicle carrier (0.9% NaCl and 0.1% 
BSA) only (n = 6). 
 
Food consumption was measured daily from 2 weeks prior to treatment through until the end 
of the study.  Daily caloric intake was calculated by multiplying the consumption of the diet 
by its caloric density provided by the manufacturer (chow: 4.15; HF: 5.43 kcal/g).  Body mass 
was recorded weekly. 
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Glucose tolerance tests, insulin stimulation and tissue collection.  Glucose tolerance tests 
were performed as per the previous chapter.  Two days after the GTT, mice were again fasted 
for 6 h (0600–1200 hours).  Blood was obtained from the tail for measurement of basal 
insulin (EDTA treatment) and FFA (EGTA/GSH treatment).  Mice were injected i.p. with 
1.5U/kg insulin.  Mice were then anaesthetised and tissues (liver, quadriceps, gastrocnemius, 
EDL, soleus, WAT, BAT, spleen) were collected 15 min after insulin injection.  All samples 
were rapidly frozen in liquid nitrogen and stored at – 80oC. 
 
Plasma Measures.  Plasma insulin was measured by ELISA (#EZRMI-13K, Linco Research, 
Missouri, USA).  FFA was measured spectrophotometrically by an enzymatic colorimetric 
assay (Wako NEFA C kit; Wako Chemicals, Richmond, VA).   
 
Tissue analysis.  All analytic methods were identical to those reported in Chapter 5. 
 
Statistical analysis.   Data was analyzed using a one way or two-way analysis of variance 
(ANOVA) with repeated measures (SPSS), with significance accepted with a P value of < 
0.05.  If analyses revealed a significant interaction, a Newman Keuls post-hoc test was used to 
locate specific differences.  Data are presented as means ± SEM. 
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6.2 Results 
 
Body Mass.  At 10 weeks of age body mass was not different between strains (WT: 28.3 ± 
0.5; IL-6-/-: 27.7 ± 0.4 g; Table 6.1).  After 10 weeks WT HF were heavier than WT chow 
(WT chow; 34.6 ± 1.4; WT HF; 39.9 ± 1.8g), but IL-6-/- chow and HF had similar body mass 
and were lighter than WT HF (IL-6-/- chow: 30.6 ± 0.8; IL-6-/- HF: 29.4 ± 1.1; P < 0.05).  By 
this age, IL-6-/- chow mice also exhibited a lower body mass than WT chow mice (P < 0.05).  
IL-6-/- mice did not display the weight gain, which WT HF did (P < 0.05).  While surgery had 
an initial effect on body mass, mice returned to their pre-surgery weight within 3-4 days.  
Neither saline- nor IL-6-treatment had deleterious effects on tissue mass (heart, spleen, 
kidney, BAT, WAT, soleus, EDL, tibialis anterior, quadriceps muscle) or body mass of mice. 
 
Food Intake.  Food intake is expressed as energy intake per day (kcal/day) and reported in 
Table 6.1.  IL-6-/- chow had a greater caloric intake than WT chow (P < 0.05), as reported in 
Chapter 5.  WT HF had a similar food intake to WT chow, whilst IL-6-/- HF ate less than 
either strain on chow (P < 0.05).  Neither saline- nor IL-6-treatment altered food consumption 
in any group.   
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Table 6.1  Food intake and body mass of WT and IL-6-/- mice on chow and HF diets two 
weeks pre- and post-saline or IL-6-treatment.  All data are expressed as mean ± SEM (n = 6). # 
P < 0.05 vs. WT; § P < 0.05 vs. Chow; † P < 0.05 vs. saline. 
 
  Wild Type IL-6 -/- 
  Chow HF Chow HF 
Body Mass     
Pre: Saline 34.6 ± 1.4 39.8 ± 1.8 § 32.3 ± 0.9 # 30.2 ± 0.7 # 
 IL-6 36.7 ± 1.1 38.9 ± 1.8 § 32.4 ± 0.8 # 29.4 ± 1.1 # § 
Post: Saline 33.9 ± 1.4 38.2 ± 1.5 § 30.6 ± 0.8 # 29.1 ± 0.9 # 
  IL-6 36.1 ± 1.5 36.8 ± 1.4 § 30.2 ± 0.4 # 28.5 ± 0.7 # § 
Food Intake     
Pre: Saline 17.9 ± 0.4 17.4 ± 0.7 19.5 ± 0.5 # 13.9 ± 0.5 # § 
 IL-6 16.9 ± 0.4 16.6 ± 0.8 18.6 ± 0.4 # 14.1 ± 0.3 # § 
Post: Saline 18.6 ± 0.4 17.2 ± 0.6 20.3 ± 0.4 # 14.2 ± 0.4 # § 
 IL-6 17.9 ± 0.2 15.1 ± 0.7 § 19.2 ± 0.5 # 13.9 ± 0.3 # § 
 
  
 
Plasma Measures 
Basal glucose levels and response to glucose tolerance test.  As seen in Chapter 5, basal 
fasting plasma glucose levels were elevated by HF in both WT and IL-6-/- mice (P < 0.05; 
Table 6.2) and glucose levels were lower in IL-6-/- chow and HF mice compared with WT 
mice (P < 0.05; Table 6.2).  Saline treatment did not alter glucose concentrations.  IL-6 
treatment increased basal glucose levels in WT and IL-6-/-, chow and HF groups (P < 0.05; 
Table 6.2).  Glucose responsiveness was assessed by measuring plasma glucose over 120 min 
following injection of a glucose bolus and then calculating the area under the curve generated 
by these measures as shown in Figure 6.1.  Saline treated mice exhibited a similar glucose 
elimination rate as reported in the previous study.  HF mice had impaired glucose tolerance, 
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as indicated by the larger area under the curve, compared with chow mice, and chow and HF 
IL-6-/- mice displayed greater glucose tolerance than WT.  IL-6-treatment impaired glucose 
tolerance in all groups (P < 0.05; Figure 6.1). 
 
Basal insulin levels and response to glucose tolerance test.  When treated with saline, insulin 
levels were greater with HF than chow in both strains (P < 0.05; Table 6.2).  IL-6-/- chow and 
HF displayed lower insulin levels than WT.  With IL-6-treatment there was an increase in 
insulin levels in WT chow (P < 0.05) and tendency for increased insulin levels in IL-6-/- 
groups, but not WT HF (Table 6.2).  AUC during the GTT for insulin measures was higher in 
HF (P < 0.05), lower in IL-6-/- (P < 0.05), and not affected by IL-6-treatment (Table 6.2). 
 
Free fatty acid.  Fasting plasma FFA was reduced approximately 30% by the HF diet in both 
mouse strains (P < 0.05, Table 6.2).  FFA was lower in IL-6-/- chow than WT chow (P < 
0.05), but not different between the strains on HF.  IL-6 treatment did not alter FFA in WT or 
HF groups, whereas increased FFA was seen in IL-6-treated IL-6-/- chow (P < 0.05). 
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Table 6.2  Basal plasma measures from 6-h fasted mice and AUC for insulin measures during 
GTT.  All data are expressed as mean ± SEM (n = 12-16).  # P < 0.05 vs. WT; § P < 0.05 vs. 
Chow; † P < 0.05 vs. saline. 
 
  Wild Type IL-6 -/- 
  Chow HF Chow HF 
Glucose (mmol)     
Post: Saline 9.3 ± 0.2 10.4 ± 0.4 § 7.0 ± 0.3 # 7.5 ± 0.3 #§ 
 IL-6 10.5 ± 0.6 † 10.2 ± 0.6 8.4 ± 0.2 # † 8.7 ± 0.3 # † 
FFA (mmol)     
Post: Saline 0.68 ± 0.09 0.39 ± 0.07 § 0.52 ± 0.04 # 0.35 ± 0.04 § 
 IL-6 0.54 ± 0.07 0.33 ± 0.03 § 0.65 ± 0.05 † 0.37 ± 0.03 § 
Insulin (ng/ml)     
Post: Saline 0.49 ± 0.04 0.64 ± 0.05 0.41 ± 0.04 # 0.55 ± 0.04 
 IL-6 0.62 ± 0.04  0.70 ± 0.06 0.50 ± 0.07  0.62 ± 0.04  
AUC (GTT insulin)     
Post: Saline 42.8 ± 2.0 65.8 ± 7.5 42.7 ± 4.9 50.3 ± 5.2 
 IL-6 48.0 ± 9.8 63.3 ± 7.5  37.2 ± 5.7 49.5 ± 4.5  
 
 
 
Diacylglycerol and ceramide content in liver tissue.  As reported in Chapter 5 and shown in 
Figure 6.2, liver DAG content was lower in IL-6-/- chow than WT chow (P < 0.05), and was 
not affected by HF.  Liver ceramide content was elevated in IL-6-/- compared with WT (P < 
0.05).  Importantly, IL-6-treatment increased both liver ceramide and DAG content in WT HF 
(P < 0.05) with no affect on any other treatment group (Figure 6.2). 
 
AMPK in skeletal muscle and liver tissue.  Phosphorylation of AMPK at Thr172 (pAMPK) was 
investigated as a measure of the activation status of AMPK.  Total AMPK protein was 
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measured and was not different between groups in either tissue.  Data is presented as pAMPK 
/ total AMPK.  IL-6 treatment decreased pAMPK in all groups in both skeletal muscle and 
liver tissue (P < 0.05) except for skeletal muscle of IL-6-/- HF (Figure 6.3).   
 
Akt in skeletal muscle and liver tissue.  IL-6 treatment increased liver Akt Ser473 
phosphorylation in all groups (P < 0.05) but did not affect gastrocnemius muscle Akt 
phosphorylation (Figure 6.4). 
 
PGC1α in skeletal muscle and liver tissue.  IL-6-treatment increased gastrocnemius muscle 
PGC1α in WT chow (P = 0.03) and there was a tendency for increased levels in IL-6-/- (P = 
0.1 chow, 0.17 HF) compared with saline-treatment.  IL-6-treatment increased PGC1α in liver 
tissue in all groups (P < 0.05; borderline significance in IL-6-/- chow P = 0.07; Figure 6.5). 
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Figure 6.1  Glucose tolerance test blood glucose (upper), area under the curve (middle) and 
plasma insulin (lower) for saline-treated (solid bars) and IL-6-treated (striped bars) WT (black 
bars) and IL-6-/- (white bars) mice.  All data are expressed as mean ± SEM (n = 6). # P < 0.05 
vs. WT; § P < 0.05 vs. Chow; † P < 0.05 vs. saline. 
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Figure 6.2  Diacylglycerol (upper) and ceramide (lower) content in liver tissue of saline-
treated (solid bars) and IL-6-treated (striped bars) WT (solid black bars) and IL-6-/- (solid 
white bars) mice.  All data are expressed as mean ± SEM (n = 6). # P < 0.05 vs. WT; § P < 
0.05 vs. Chow; † P < 0.05 vs. saline. 
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Figure 6.3  AMPK phosphorylation relative to total AMPK protein in gastrocnemius muscle 
(upper) and liver tissue (lower) of saline-treated (solid bars) and IL-6-treated (striped bars) 
WT (solid black bars) and IL-6-/- (solid white bars) mice.  All data are expressed relative to 
saline-treated WT chow as mean ± SEM (n = 6). # P < 0.05 vs. WT; § P < 0.05 vs. Chow; † P 
< 0.05 vs. saline. 
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Figure 6.4  Akt Ser473 phosphorylation in gastrocnemius muscle (upper) and liver tissue 
(lower) of saline-treated (solid bars) and IL-6-treated (striped bars) WT (solid black bars) and 
IL-6-/- (solid white bars) mice.  All data are expressed relative to saline-treated WT chow as 
mean ± SEM (n = 6). # P < 0.05 vs. WT; § P < 0.05 vs. Chow; † P < 0.05 vs. saline. 
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Figure 6.4  PGC1α protein in gastrocnemius muscle (upper) and liver tissue (lower) of saline-
treated (solid bars) and IL-6-treated (striped bars) WT (solid black bars) and IL-6-/- (solid 
white bars) mice.  All data are expressed relative to saline-treated WT chow as mean ± SEM (n 
= 6). # P < 0.05 vs. WT; § P < 0.05 vs. Chow; † P < 0.05 vs. saline. 
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6.3 Discussion 
 
The main finding of this study is that chronic IL-6 treatment impairs glucose tolerance and 
AMPK activity in both IL-6-/- and WT mice.  Of note, when treated with rmIL-6, mice on a 
standard chow diet had elevated basal glucose levels while basal insulin levels tended to 
increase with this treatment.  Moreover, in all groups of mice tested, IL-6 treatment induced 
glucose intolerance.  Importantly, with respect to both basal glycemia and glucose tolerance, 
the response to IL-6 treatment was similar in both WT and IL-6-/- mice, despite the fact that 
the mice were of different genetic background.  In addition, the results from this study, which 
show that “gain of function” with respect to IL-6 produced a negative phenotype, are 
consistent with the results from the previous chapter, which showed that “loss of function” 
produced a positive phenotype.  These current findings support previous experiments in mice 
that showed that IL-6 induced insulin resistance (Klover et al., 2003; Kim et al., 2004b; 
Klover et al., 2005).  Hence, based on these series of experiments it appears that IL-6 induces 
glucose intolerance in mice. 
 
As discussed in the introduction of this chapter, the studies in mice appear to be in conflict 
with studies conducted in humans (Petersen et al., 2005a) or in rats (Rotter Sopasakis et al., 
2004; Chapter 7 of this thesis).  The data presented here are supported by an number of in vivo 
studies where IL-6 is seen to impair insulin sensitivity (Klover et al., 2003; Kim et al., 2004b; 
Cai et al., 2005).  Klover and colleagues demonstrated defects in downstream actions of 
insulin in mice chronically treated with IL-6.  These mice presented with abnormal insulin 
tolerance test, increased postprandial serum glucose levels, and reduced postprandial 
induction of glucokinase (Klover et al., 2003).  Kim and colleagues showed that IL-6 
treatment lowered GIR, whole body glucose turnover, skeletal muscle glucose uptake, muscle 
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and liver insulin signalling, and increased hepatic glucose production (Kim et al., 2004a).  Cai 
and colleagues reported that mice presenting with profound hepatic, and moderate systemic 
insulin resistance exhibited elevated IL-6 production (Cai et al., 2005).  When IL-6 was 
systemically neutralised the insulin resistant phenotype was reversed (Cai et al., 2005).  
Together, these data demonstrate that chronic exposure to circulating levels of IL-6 that are 
within the range attainable in obesity and type 2 diabetes are able to recapitulate several of the 
characteristic metabolic defects of obesity-mediated insulin resistance and diabetes.  It is 
difficult to determine why there should be such species differences, but it is important to note 
that while insulin treatment results in 100% suppression of hepatic glucose production in 
humans (Petersen et al., 2000) and rats (Watt et al., 2006), hepatic glucose output is only 
suppressed ~70% in mice (He et al., 2003; Hevener et al., 2003).  This may be an important 
consideration when examining the effect of IL-6 on metabolic processes in various species. 
 
Investigation into accumulation of fatty acid species in liver tissue after IL-6 treatment did not 
account for impaired glucose tolerance as DAG and ceramide levels were only elevated in 
WT HF, despite the development of glucose intolerance in all groups.  Further investigation 
into the lipid profile of other tissues is warranted, as tissue-specific differences are likely.  IL-
6 treatment decreased phosphorylation of AMPK in liver in all groups, with a less prominent 
phenotype observed in gastrocnemius muscle.  Such a profound affect on AMPK activity 
would more than likely decrease fatty acid oxidation and glycolysis to contribute to glucose 
intolerance.  Fatty acid metabolism and oxidation could be investigated in specific tissues to 
verify this.  The finding of decreased AMPK activity is consistent with impaired glucose 
tolerance; however, it is at odds with the knowledge that IL-6 is released from skeletal muscle 
in large amounts during and after sustained physical activity (Febbraio & Pedersen 2002) and 
that AMPK activity is increased several fold following exercise (Vavvas et al., 1997).  Kelly 
and colleagues incubated isolated rat skeletal muscles in the presence of IL-6 and observed 
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increases in AMPK phosphorylation (Kelly et al., 2004).  The same investigation reported 
diminished AMPK activity in IL-6 knockout mice at rest and following exercise.  It is 
difficult to resolve the discrepancy between the results of Kelly and colleagues and those of 
the current study as experimental conditions and data presented do not allow for comparisson.  
Furthermore, in our hands, in vivo IL-6 treatment in rats does not alter AMPK activity 
(Chapter 7). 
  
In conflict with decreased AMPK activity in the current study, IL-6 treatment increased 
phosphorylation of the transcription factor, PGC1α, which is a key regulator of metabolic 
processes, such as oxidative phosphorylation, liver gluconeogenesis, and mitochondrial 
biogenesis (Spiegelman et al., 2000; Scarpulla, 2002; Puigserver & Spiegelman, 2003).  
Increased activation of PGC1α in liver and muscle tissue is not consistent with the observed 
glucose intolerance in IL-6 treated mice and, as such, this result was unexpected.  Likewise, 
increased phosphorylation of Akt in liver with IL-6 treatment was unexpected.  However, 
chronic activation of Akt may contribute to insulin resistance in insulin-sensitive tissues as 
hypothesised by Carey and Febbraio (Carey & Febbraio, 2004). 
 
In conclusion, we demonstrate that IL-6 treatment impairs glucose tolerance.  Furthermore, 
this investigation supports the findings of the previous study that the deficit of IL-6 improves 
glucose tolerance and insulin sensitivity.  That IL-6 treatment impaired glucose tolerance in 
both strains of mice enables us to further ascribe the improved insulin sensitivity in IL-6-/- 
mice to IL-6 deficiency per se rather than differences in background.   
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CHAPTER SEVEN 
 
 
PROLONGED IL-6 TREATMENT IMPROVES GLUCOSE 
TOLERANCE BUT NOT INSULIN SENSITIVITY IN RATS 
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7.1 Introduction  
 
 
The results presented in first two experimental chapters of this thesis, demonstrated that IL-6 
is produced by skeletal muscle in response to calcium (Chapter 3), and that the exercise-
induced production and release of IL-6 is exacerbated with suppression of lipolysis (Chapter 
4).    Over 5 years ago, Steensberg and colleagues first reported that IL-6 is produced from 
contracting muscle (Steensberg et al., 2000) and since that time several papers ((Keller et al., 
2001; Starkie et al., 2001a; Steensberg et al., 2001a; Hiscock et al., 2003; Febbraio et al., 
2004; Hiscock et al., 2004; Tomiya et al., 2004; Keller et al., 2005a; Keller et al., 2005b) 
have verified that IL-6 is produced and released by skeletal muscle during exercise.  It is 
important to note, that during exercise muscle glucose uptake in markedly increased 
compared with rest.  These exercise studies, coupled with studies conducted in a muscle cell 
culture model where IL-6 was acutely administered (Weigert et al., 2006), suggest that during 
contraction, IL-6 may be produced to activate signalling pathways to increase glucose uptake.  
 
In contrast with the acute cell culture model (Weigert et al., 2005), experiments reported in 
Chapter 6 of this thesis, along with those reported by Mooney and co-workers (Senn et al., 
2002; Klover et al., 2003; Senn et al., 2003), clearly demonstrate that chronic IL-6 
administration in the mouse impairs insulin sensitivity.    Why would this apparent paradox 
exist?  Careful examination of the literature generally suggests that acute IL-6 treatment in 
vivo results in positive effects with respect to insulin sensitivity, whereas chronic IL-6 
treatment has the opposite effect.  Highlighting this notion is the fact that athletes, who 
experience frequent saccadic increases in IL-6 following training, are profoundly insulin 
sensitive.  Furthermore, that IL-6 is rapidly cleared following infusion (Steensberg et al., 
2003a; van Hall et al., 2003) or exercise (Steensberg et al., 2001a), suggests that chronic 
elevation may be undesirable. In a recent review, Carey and Febbraio (2004) put forward the 
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hypothesis chronic elevations in IL-6, such as in obesity and type 2 diabetes, may impair 
insulin sensitivity in insulin-responsive cells by serine phosphorylation of IRS1, which would 
down-regulate PI3K via activation of the mammalian target of rapamycin (mTOR), which is 
activated by Akt (Takano et al., 2001; Tremblay & Marette, 2001; Gual et al., 2003).  IL-6 
may also inhibit tyrosine phosphorylation of IRS1 by activating suppressors of cytokine 
signalling (SOCS1/3) via the Jak/STAT pathway.  The acute elevation of IL-6 however may 
not be sufficient for the activation of mTOR as the short stimulation may not cause chronic 
Akt activation (Figure 7.1).  In this study we sought to test the hypothesis proposed by Carey 
& Febbraio (2004).  Our aim was to exogenously administer IL-6 to rats eliciting either 
chronic or acute elevations in systemic IL-6 and investigate the subsequent effect on whole 
body glucose tolerance and insulin sensitivity.  We chose the rat as a model for study for 2 
reasons. Firstly, since the rat is ~10 times greater in mass compared with a mouse we could 
comprehensively examine metabolites and signalling molecules in many tissues in the single 
animal.  Secondly, and more importantly, under conditions of insulin stimulation the rat 
behaves more like the human than the mouse.  Specifically, during a hyperinsulinemic 
euglycemic clamp both rats (Watt et al., 2006) and humans (Petersen et al., 2005b) display 
100% suppression, whereas mice only display ~50-70 % suppression (Hevener et al., 2003) of 
hepatic glucose output. We hypothesised that the mode of IL-6 treatment would have 
divergent effects on these parameters in an in vivo setting. 
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Figure 7.1  Hypothesised role for IL-6 in the aetiology of insulin sensitivity within insulin 
responsive cells (From Carey & Febbraio, 2004. "Interleukin-6 and insulin sensitivity: friend 
or foe?" Diabetologia 47: 1135-1142). 
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7.2 Methods 
 
Animals.  Male Wistar rats weighing approximately 220 g were purchased from Monash 
Animal Facility (Clayton, Victoria, Australia).  The animals were housed in the RMIT 
University animal facility in a controlled environment with a 12:12 hour light:dark cycle and 
fed rat chow and water ad libitum.  All experimental procedures were approved by the Animal 
Ethics Committee of RMIT University (AEEC #0407).  Animals were randomly assigned to 
receive IL-6 or saline vehicle in a chronic or phasic manner, with 12 animals in each group. 
 
IL-6 treatment: Chronic.  For experiments examining chronic IL-6 exposure, osmotic pumps 
(Alzet 2ML2; Durect, Cupertino, CA) with a 14-day pumping capacity and an infusion rate of 
4.5 µl/h were used.  Pumps were filled to capacity with 22.5 µg/ml rhIL-6 diluted in carrier 
(0.9% NaCl and 0.1% BSA) resulting in a daily delivery of 2400 ng rhIL-6.  Following 
induction of general anaesthesia with sodium pentobarbital (6 mg.100 g-1 bw; Sigma), pumps 
were implanted into the intrascapular subcutaneous space. Incisions were closed with 
interrupted absorbable sutures.  Control animals received pumps containing the carrier alone 
(herein referred to as Control). 
 
IL-6 treatment: Phasic.  Phasic IL-6 treatment was achieved by injecting rats with 2400 ng 
rhIL-6 into the i.p. space twice daily.  1200 ng rhIL-6 diluted in carrier (0.9 % NaCl and 0.1 
% BSA) was injected at 0700 and 1900 daily for 14-days.  Control animals received saline 
injections of the same volume at the same time. 
   
Insulin and glucose tolerance tests.  Rats were fasted for 12 h overnight and tested at 0700 on 
day 14.  Basal blood samples (t = 0) were taken from the tail of restrained rats for blood 
glucose and plasma insulin measures.  For glucose tolerance tests 1 g.kg-1 bw glucose was 
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injected intraperitoneally.  Blood samples for measurement of glucose and plasma insulin 
levels were obtained from the tail at 15, 30, 60, and 120 min.  For insulin tolerance tests 0.75 
U. kg–1 bw insulin (recombinant human insulin; Actrapid) was injected intraperitoneally.  
Blood samples for glucose measurement were obtained from the tail at 15, 30, 60, and 120 
min. 
 
Tissue collection.  Approximately 24-hours after tolerance testing rats were anaesthetised (6 
mg.100 g-1 bw sodium pentobarbital; Sigma, Steinheim, Germany), and injected with insulin 
(150 mU.g-1) or saline vehicle intraperitoneally.  After approximately 10 min soleus, 
gastrocnemius, liver and adipose tissues were excised and rapidly frozen in liquid nitrogen for 
storage at –80oC. 
 
Plasma Analysis.  Glucose measures were assessed immediately at the time of blood 
collection using a HemoCue Glucose 201+ Analyser (HemoCue, Ängelholm, Sweden).  Free 
fatty acid content (FFA) was measured spectrophotometrically by an enzymatic colorimetric 
assay (Wako NEFA C kit; Wako Chemicals, Vancouver, USA).   
 
Analysis of muscle and liver triacylglycerol.  Analytic methods were identical to those 
reported in Chapter 5.  
 
Tissue protein extraction, immunoblotting and western blot analysis.  Analytic methods were 
identical to those reported in Chapter 5.  All values reported are expressed relative to control. 
 
AMPK Activity.  Analytic methods were identical to those reported in Chapter 5.   
 
Statistical Analyses.  Data was analyzed using a one way or two-way analysis of variance 
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(ANOVA) with repeated measures (SPSS), with significance accepted with a P value of < 
0.05.  If analyses revealed a significant interaction, a Newman Keuls post-hoc test was used to 
locate specific differences.  Data are presented as means ± SEM. 
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7.3 Results 
 
No differences in any measures were observed between phasic saline- and chronic saline-
treated groups.  Hence, data from these two groups were pooled and are henceforth referred to 
as control (Con). 
 
IL-6 enhances whole body glucose tolerance irrespective of mode of delivery.  Fasting basal 
blood glucose was not different between any of the groups.  The glucose bolus administered 
for the glucose tolerance test (GTT) elicited an ~ 2.4-fold increase in blood glucose 
concentration at 15 min in Con rats (P < 0.05).  The glucose concentration in both groups of 
IL-6-treated rats was elevated ~ 1.8-fold over basal levels 15 min after administration of the 
glucose bolus (P < 0.05).  This increase was lower in IL-6-treated rats than that of Con rats (P 
< 0.05).  During the GTT, glucose was consistently lower in both phasic and chronic IL-6-
treated rats than in Con.  When glucose measures were expressed as area under the curve 
(AUC) for the duration of the GTT, AUC for both IL-6-treated groups was ~ 30 % lower than 
Con (P < 0.05) and this was not different between phasic or chronic IL-6 treatment.  At the 
120 min time point glucose of all rats was ~ 10 % above fasting basal levels (Figure 7.2). 
 
IL-6 does not effect whole body insulin tolerance, insulin signalling or lipid metabolite 
accumulation in muscle and liver irrespective of mode of delivery.  The insulin bolus 
administered decreased blood glucose at all time points in all groups relative to fasting basal 
values (P < 0.05).  Although there was a slight tendency for glucose to be lower at 30 min 
when comparing phasic IL-6 with Con, the results were not significant differences in blood 
glucose were observed between the groups at any time point during the ITT (Figure 7.3).  
Consistent with this finding, although insulin stimulation increased phosphorylation of Akt 
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(Ser473) in muscle and liver tissue (P < 0.05), no differences were observed when comparing 
the groups (Figure 7.4).  Since IL-6 has been known to increase lipolysis and lipid oxidation 
(van Hall et al., 2003; Petersen et al., 2005a), we next sought to determine if IL-6 treatment 
influenced triglyceride content in skeletal muscle (soleus) or liver tissue, but this was not the 
case (Figure 7.5).   
 
IL-6 treatment does not affect AMPK signalling in skeletal muscle or liver, but decreases 
AMPK in adipose tissue.  Since acute IL-6 treatment activates AMPK (Kelly et al., 2004) we 
next sought to determine the effect of chronic IL-6 treatment on AMPK and downstream 
signalling.  IL-6 treatment did not alter activity of the AMPK subunits, α1 and α2, in EDL 
muscle or liver tissue, nor did effect phosphorylation of ACC in liver.  There was, however, a 
small but significant decrease in p-ACC in EDL with chronic, but not phasic IL-6 treatment.  
Chronic IL-6 treatment decreased AMPK α1 activity in WAT compared with Con (P < 0.05) 
but no differences were seen between the IL-6 treated groups or between Con and IL-6 Phasic 
(Figure 7.6).  However, this effect was not matched by a reduction in p-ACC with chronic 
treatment (Figure 7.7).     
 
IL-6 treatment increases PPAR alpha and UCP2 protein content in skeletal muscle tissue.  
IL-6 is a potent lipolytic factor (van Hall et al., 2003; Petersen et al., 2005a) and has been 
shown to enhance whole body VO2 in rats (Wallenius et al., 2002a).  Since fatty acids can 
enhance UCP levels in myocardium via a PPAR dependent mechanism, we next sought to 
determine whether IL-6 increased PPAR and UCP isoforms.  Phasic IL-6 treatment increased 
PPARα content in tibialis anterior muscle compared with Con (P < 0.05) but no differences 
were seen between other groups or the PPAR γ and δ isoforms (Figure 7.8).  Both phasic and 
chronic IL-6 treatment increased UCP2 content in tibialis anterior muscle compared with Con 
(P < 0.05) but no differences were seen in UCP3 content (Figure 7.9).   
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IL-6 treatment does not affect GLUT4, STAT or mTOR signalling or markers of inflammation.  
No differences were seen in skeletal muscle GLUT4, SOCS3, STAT3 phosphorylation 
(Tyr705), NFβκ, IKβ-α phosphorylation (Ser32/36) mTOR phosphorylation (Ser2448), or 
p70 S6K (Figure 7.10).  No differences were seen in liver tissue SOCS3 or IKβ-α 
phosphorylation (Ser32/36) (Figure 7.11). 
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Figure 7.2  Glucose measures (upper) and area under the curve (lower) for glucose tolerance 
tests (1 g.kg bw-1) of saline-treated control (▬■▬, black bars), phasic IL-6-treated (---◊---, 
striped bars), and chronic IL-6-treated (▬◊▬, open bars) rats.  All data are expressed as 
mean ± SEM (n = 12). # P < 0.05 vs.  
# # # # 
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Figure 7.3  Glucose measures for insulin tolerance tests (0.75 U.kg bw-1) of saline-treated 
control (▬■▬), phasic IL-6-treated (---◊---), and chronic IL-6-treated (▬◊▬) rats.  All data 
are expressed as mean ± SEM (n = 12).  
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Figure 7.4 Akt protein content and Ser473 phosphorylation of basal (B) or insulin-stimulatied 
(I) tibialis anterior muscle (upper) and liver tissue (lower) of saline-treated control (solid 
black bars, S), phasic IL-6-treated (striped bars, P), and chronic IL-6-treated (open bars, C) 
rats.  Representative blots are shown.  All data are expressed as mean ± SEM (n = 6). * P < 
0.05 vs. basal.  
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Figure 7.5  Triacyglycerol content of soleus muscle (left) and liver tissue (right) of saline-
treated control (solid black bars), phasic IL-6-treated (striped bars), and chronic IL-6-treated 
(open bars) rats.  All data are expressed as mean ± SEM (n = 12).  
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Figure 7.6  AMPK α1 and α2 subunit activity in EDL muscle (upper), liver (middle), and 
adipose tissue (lower) of saline-treated control (solid black bars), phasic IL-6-treated (striped 
bars), and chronic IL-6-treated (open bars) rats.  All data are expressed as mean ± SEM (n = 
12). # P < 0.05 vs. Con. 
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Figure 7.7  ACC phosphorylation of EDL muscle (upper), liver tissue (middle), and white 
adipose tissue (lower) of saline-treated control (solid black bars), phasic IL-6-treated (striped 
bars), and chronic IL-6-treated (open bars) rats.  All data are expressed as mean ± SEM (n = 6).  
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Figure 7.8  PPAR isoforms in tibialis anterior muscle tissue of saline-treated control (solid 
black bars), phasic IL-6-treated (striped bars), and chronic IL-6-treated (open bars) rats.  All 
data are expressed as mean ± SEM (n = 6).  # P < 0.05 vs. Con. 
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Figure 7.9  Uncoupling protein 2 and 3 content in  tibialis anterior muscle tissue of saline-
treated control (solid black bars), phasic IL-6-treated (striped bars), and chronic IL-6-treated 
(open bars) rats.  All data are expressed as mean ± SEM (n = 6).  # P < 0.05 vs. Con. 
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Figure 7.10  Representative blots of GLUT4, SOCS3, STAT3 (Tyr705), NFκB, IκBα (Ser32/36), 
mTOR (Ser2448), and p70 S6K protein content in basal and insulin stimulated tibialis anterior 
muscle tissue of control, phasic IL-6-treated, and chronic IL-6-treated rats.  No differences 
were observed between the groups. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.11  Representative blots of SOCS3, p-IκBα (Ser32/36), and IκBα protein content in 
basal and insulin stimulated liver tissue of control, phasic IL-6-treated, and chronic IL-6-
treated rats.  No differences were observed between the groups. 
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7.4 Discussion 
 
A common perception is that chronically elevated levels of IL-6 in obesity and disease states 
promotes insulin resistance (Lazar, 2005).  Yet in light of the positive effects of exercise on 
insulin sensitivity, it is also believed that the acute exercise-induced increases in IL-6 have a 
beneficial effect on metabolism and insulin sensitivity (Febbraio & Pedersen, 2005).  The 
results from this study show that rhIL-6 treatment does not impair glucose tolerance or insulin 
signalling in rats at the peripheral level, but rather, improves insulin-stimulated glucose 
disposal during a glucose tolerance test.  Furthermore, chronic and phasic elevations in 
exogenous IL-6 do not exhibit divergent effects.   
 
According to the insulin tolerance test data, neither phasic nor chronic IL-6 treatment 
impaired insulin sensitivity in peripheral tissues, which was corroborated by normal insulin-
stimulated Akt phosphorylation in skeletal muscle and liver tissue.  Likewise, IL-6 treatment 
did not affect proteins associated with inflammation and insulin resistance in muscle tissue as 
we hypothesized would occur with chronic IL-6 treatment.   Consistent with this finding, 
rhIL-6 infusion during a hyperinsulinemic-eyglycemic clamp in rats has recently been shown 
to have no effect on whole body glucose disposal or insulin sensitivity (Rotter Sopasakis et 
al., 2004).  Other investigators report contradictory findings, albeit in a different species.  
Klover and colleagues demonstrated defects in downstream actions of insulin in mice 
chronically treated with IL-6 (Klover et al., 2003).  These included abnormal response to an 
insulin tolerance test, increased postprandial serum glucose levels, and reduced postprandial 
induction of glucokinase.  These data demonstrated that chronic exposure to circulating levels 
of IL-6 induced hepatic insulin resistance without impairing skeletal muscle insulin signalling 
(Klover et al., 2003).  Accounting for body weight, this dose was approximately 2-fold 
greater than used in the current study.  Another study, by Kim and colleagues, reported that 
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mice acutely treated with recombinant murine IL-6 before or during an hyperinsulinemic-
euglycemic clamp experienced impaired glucose disposal and insulin signalling (Kim et al., 
2004a).  Impairments were observed in insulin-stimulated IRS1- and IRS2-associated PI3K 
activation in skeletal muscle and liver, respectively, with skeletal muscle showing greater 
degree of impairment than liver tissue (Kim et al., 2004a); contrary to the findings of Klover 
and colleagues (Klover et al., 2003).  The dose of IL-6 administered in the above mouse study 
(0.5 mg/h/mouse) far exceeded that employed in the current study (100 ng/h/rat) and thus 
raises concerns over the physiological relevance of such results.  Even so, in the previously 
mentioned mouse study insulin-stimulated Akt activity was not affected in either tissue type 
(Kim et al., 2004a).  It is difficult to ascertain what comparisons can be made between studies 
utilising different species.  During hyperinsulinemic-euglycemic clamps various mouse 
strains exhibit glucose infusion rates often 5-10-fold greater than those of various rat strains, 
meaning that mice have far greater rates of insulin-stimulated glucose uptake.  Thus mice are 
much more insulin sensitive than rats and are likely to have alternate sensitivity to and 
regulation of such interventions, which may account for the detrimental results observed in 
mice but not in rats.   Furthermore, in support of our findings Carey and colleagues recently 
conducted a 4-h IL-6 infusion in healthy human subjects, which improved whole body 
glucose disposal, oxygen consumption, glucose oxidation, and insulin sensitivity and did not 
impair insulin’s ability to suppress hepatic glucose production (Carey et al., in review after 
revision).   
 
The finding of improved glucose tolerance in IL-6-treated rats during the first 60 min of the 
GTT was a consistent finding across all animals.  However, without further investigation into 
regulation of glucose metabolism at the level of the liver, we cannot rule out this being a 
transient effect, with questionable physiological relevance.  IL-6-treatment may have affected 
food-seeking behaviour, thus increasing activity and energy expenditure, which could account 
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for the observed improvement in glucose tolerance, however, food intake and activity patterns 
of rats were not monitored.  We observed increases in both PPARα and UCP2 protein 
expression in skeletal muscle of IL-6 treated rats.  The physiological relevance of these 
increases may indeed be marginal, however both of these proteins play integral roles in the 
regulation of metabolism, particularly that of fatty acid oxidation.  IL-6 may be enhancing fat 
oxidation by way of PPARα.  Alternatively, the increase in PPARα may be a negative 
feedback response to the circulating IL-6 levels as PPARα has previously been shown to 
inhibit activation of IL-6 (Chinetti et al., 2000; Gervois et al., 2004).  The effect of IL-6 on 
UCP expression has not been studied and requires investigation.  Previous reports 
demonstrated increased VO2 following rhIL-6 treatment into rats (Wallenius et al., 2002a) 
and humans (Carey et al., in review after revision), which increased insulin-stimulated 
glucose disposal and appeared to be due to enhanced oxidative glucose metabolism.  As such, 
we suggest that IL-6 may be augmenting cellular respiration leading to an increase in glucose 
oxidation by increasing mitochondrial uncoupling. 
 
It should be noted as an element of concern that the pharmacological effect of a given 
cytokine may differ from its biological effect.  Issues arising from exogenous administration 
of compounds have been previously highlighted.  For example, the use of anti-IL-6 antibodies 
to abrogate circulating IL-6 levels has been suggested to enhance IL-6 release and has been 
shown to in fact have the opposite effect whereby it increased the bioactivity of circulating 
IL-6 (Heremans et al., 1992).  The low homology between human and rat IL-6 (~58 %) is of 
concern and may account for the absence of a phenotype developed in IL-6-treated rats.  rhIL-
6 has previously been reported to elicit effects in rodent brain tissue (Schobitz et al., 1995; 
van der Meer et al., 1996), hepatocytes (Schieferdecker et al., 2000; Moran et al., 2005) and 
skeletal muscle (Baudry et al., 1996), with similar effects seen with rhIL-6 and rrIL-6 
(Schieferdecker et al., 2000).  Other studies have reported that exogenous rhIL-6 treatment in 
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rodents is efficacious providing it is supplemented with soluble recombinant human IL-6Rα 
(Marz et al., 1997; Marz et al., 1999; Thier et al., 1999; Galun et al., 2000).  A previous study 
treating rats systemically with rhIL-6 has also reported a null effect (Rotter Sopasakis et al., 
2004), yet  rats treated intracerebroventricularly with rodent IL-6 exhibit profound results 
(Wallenius et al., 2002a).  The homology between human and mouse IL-6 is even lower; at 
~42 %.  Given that rhIL-6 of similar concentrations to that used in the current study has been 
administered to mice and has been observed to have detrimental outcomes on insulin 
signalling (Klover et al., 2003), it is unlikely that rhIL-6 used in this study was without 
biological function in the rats.  The divergent outcomes in response to IL-6 may be species-
specific.  This notion is highlighted by the fact that the results of this study are in contrast to 
that of the previous study (Chapter 6) whereby; administration of equivalent doses of IL-6 (kg 
bw-1) elicited quite different results in mice to that in rats in the current study.  Admittedly, 
mice were treated with rmIL-6 and rats, rhIL-6.  An investigative comparison of human, 
rodent and murine IL-6 bioactivity and elimination within and across species is warranted.  
 
The observation of elevated IL-6 levels in the circulation and adipose tissue of type 2 diabetic 
patients has been instrumental in the notion of IL-6 as a cause of insulin resistance (Carey & 
Febbraio, 2004).  A substantial portion of circulating IL-6 is released from adipose tissue at 
rest (Mohamed-Ali et al., 1997), and increased circulating IL-6 levels in type 2 diabetic 
patients have been shown to be related to fat mass and not insulin sensitivity (Carey et al., 
2004).  Furthermore, IL-6 production and release from contracting skeletal muscle positively 
correlates with muscle glucose uptake during contraction (Steensberg et al., 2001a).  This 
study found that exogenous rhIL-6 did not effect insulin sensitivity but did somewhat improve 
insulin-stimulated glucose disposal.  Thus we propose that exogenous IL-6 administration 
does not cause insulin resistance as the augmented secretion of IL-6 in obesity and insulin 
resistance is a response to the obese insulin resistant state, rather than a cause of insulin 
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resistance.   Further investigation needs to be conducted into clarifying the effect of IL-6 on 
metabolic parameters in various species and tissue types and delineating efficacious doses of 
IL-6 in both chronic and acute conditions. 
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CHAPTER EIGHT 
 
 
  SUMMARY AND CONCLUSIONS 
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8.1 Summary and Conclusions 
 
The primary aim of this thesis was to investigate the role of interleukin-6 in insulin sensitivity 
and fat metabolism in states of metabolic health and disease. 
 
The first study (Chapter 3) found that skeletal muscle IL-6 mRNA and protein were up-
regulated in vitro in a calcium-dependent manner, specifically, in response to the calcium 
ionophore, ionomycin, but not in response to high physiological concentrations of adrenaline.  
In the literature, IL-6 production during exercise is attributed with having a role in the 
regulation of lipolysis, and during exercise, plasma adrenaline and IL-6 levels are closely 
correlated.  Adrenaline is known to have a profound effect on fuel metabolism and thus the 
concept that adrenaline might cause the increase in IL-6 production associated with exercise 
had previously been raised.  However, this was the first study to examine the effect of 
adrenaline per se on IL-6 production within and from skeletal muscle and it indicated that in 
physiological situations adrenaline per se does not induce IL-6.  The second study (Chapter 4) 
verified the exercise-induced increase in circulating IL-6 and demonstrated that both the 
contracting skeletal muscle and adipose tissue contribute to this by increasing IL-6 gene 
expression within the tissue.   This study further investigated the role of IL-6 in the regulation 
of fat metabolism by preventing the utilisation of fatty acids as a metabolic substrate in both 
the resting and exercising state in healthy human subjects.  The most important findings of 
this study (Chapter 4) were firstly, that when fatty acid release was inhibited IL-6 levels 
increased in both the resting and exercising conditions, and secondly, that under these 
conditions the increase in IL-6 mRNA within adipose tissue was marked.  These studies are 
important as they add weight to the body of literature which indicates that IL-6 per se is 
produced in and released from metabolically sensitive tissues in metabolically demanding 
circumstances and plays a part in the regulation of fat metabolism in humans (Figure 8.1).  
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This study would benefit from extending the investigation to include the infusion of lipid 
concomitantly with NA ingestion and exercise.  Furthermore, given the apparent species-
specific differences, theses investigations in rodents are warranted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1  Schematic presentation of the biological effect of muscle derived IL-6 on adipose 
tissue.  (Adapted from Febbraio & Pedersen FASEB J. 16 : 1335-1347, 2002) 
  
 
Having concluded from the first two studies that IL-6 was likely involved in the regulation of 
energy utilisation in humans, and the previous investigation reporting IL-6 knockout mice to 
be obese and insulin resistant, the third study (Chapter 5) aimed to investigate the 
mechanisms underlying the insulin resistance and altered metabolic state of mice deficient in 
IL-6.  The IL-6-/- mice we investigated in this study were markedly insulin sensitive, but were 
IL-6 
FFA release
IL-6
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similarly affected by a high-fat diet as WT mice were.  It is however, important to be mindful 
that this study alone does not add to the literature in a particular regard, but serves as an 
important warning for researchers to be careful in the planning of their experiments so as to 
ensure appropriate controls are conducted.  The issues raised in the discussion (Chapter 5) 
make it very difficult to interpret the data from this study as to the effect of the absence of IL-
6 within the system.  The importance of the strain background and health status of the animal 
can not be understated.  In future, when employing genetically modified models researchers 
need to be especially diligent in ensuring the purity of the breeding line they are using and 
fully characterising the strain both with and without the genetic modification.  Additionally, 
the health of animals needs to be thoroughly assessed regularly and rigorous procedures 
adhered to within the breeding facility in order to ensure no diseases compromise the colony’s 
health.   
 
By adopting a “gain of function” approach and treating mice with IL-6 we attempted to 
validate the results from the “loss of function” study in Chapter 5.  An investigation into the 
mechanisms of food regulation would be of interest in these groups of mice as underlying 
differences at this level were not addressed and may provide a better understanding of the 
aetiology.  Whilst the absence of diet-induced differences between the strains in Chapter 5 
indicated that the background, rather than the IL-6 deficiency, was the likely cause of 
differences in insulin sensitivity, the IL-6 treatment indicated to the contrary.  In all groups of 
mice tested, IL-6 treatment induced glucose intolerance.  Importantly, with respect to both 
basal glycemia and glucose tolerance, the response to IL-6 treatment was similar in both WT 
and IL-6-/- mice, despite the fact that the mice were of different genetic background.  The 
phenotype of the IL-6-/- mice appeared to be mediated by improved fat metabolism as relevant 
measures were increased basally and impaired by IL-6 treatment.  These analyses were not 
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conducted as thoroughly as is perhaps warranted following IL-6 treatment but this is an 
avenue for future investigation.   
 
These observations of negative effects of IL-6, quite disparate to those made in humans, are 
potentially due to the fact that the two species regulate metabolic parameters differently, 
rather than being a manifestation of genetic manipulation per se, as indicated by the reversal 
of the phenotype with IL-6 treatment.  Such species-specific differences are particularly 
apparent when performing a hyperinsulinemic-euglycemic clamp.  A maximal insulin dose 
suppresses glucose production by ~50-70% in healthy mice, compared with ~100% 
suppression in humans, indicative of the increased hepatic sensitivity to insulin in humans, yet 
mice display ~10-fold greater rates of insulin-stimulated glucose uptake than humans 
indicating greater insulin sensitivity at a whole body level. 
 
We then went on to investigate the effect of exogenous IL-6 in rats (Chapter 7).  This study 
was to serve two purposes; firstly, to enable us to make another species comparison of the 
effect of IL-6, secondly, and most importantly, to determine whether discrepancies in the 
literature concluding positive, null, and negative effects of IL-6 on insulin sensitivity could be 
attributed to the mode of administration being either acute of chronic.  Analysis revealed no 
differences due to the mode of IL-6 treatment.  Although the dose of IL-6 in this study was 
comparable to that in the mouse study (Chapter 6) it did not impair insulin sensitivity in the 
rats, and actually improved glucose tolerance.  Again, these results are quite different to those 
in mice following IL-6 treatment (Figure 8.2).  These results further support the notion that 
there are pertinent species-specific differences in metabolic regulation and response to IL-6 
which require further investigation. 
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Figure 8.2  Contrasting effects of 14-day IL-6 treatment on glucose tolerance of rats (left) and 
mice (right) 
 
 
In conclusion, this thesis suggests that the factor which contributes most pertinently to the 
controversy in the literature with respect to IL-6 having positive and negative effects on 
insulin sensitivity is the species studied.   On the whole, it would appear that IL-6 has 
beneficial metabolic effects in humans, particularly with respect to substrate utilisation and 
unfavourable effects in mice regarding insulin sensitivity.  Ongoing investigations will 
hopefully tease out the differences in metabolic regulation between the rodent species 
commonly studied and that of humans.  By being aware of the similarities and differences 
between species this knowledge will in turn assist future experimenters direct their 
investigations in an appropriate manner so as to ultimately resolve the components important 
in insulin sensitivity and other metabolic processes in order to treat the likes of obesity and 
type 2 diabetes.   
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